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Abstract 
One of the hallmarks of immune system \z the tremendous potentiality to 
discriminate between self and non-self. Systemic Lupus Erythematosus (SLE) - a 
prototype autoimmune disorder, Is a chronic, life-long and potentially fatal 
disease, which is characterized by unpredictable exacerbations and remissions 
with protean clinical manifestations. SLE is a complex disorder affecting 
predominately young populations and shares similarities with HIV infection which 
is well known associated with tuberculosis (HIV-Tuberculosis) as regards the 
propensity for multiple organ involvement, potentially life-threatening episodes, 
and need for sophisticated monitoring. The clinical features of SLE are protean 
and may mimic infectious mononucleosis, lymphoma, or other systemic disease. 
The origin of autoantibody production in SLE is still poorly understood till date. 
However, a role has been suggested for an antigen driven process, spontaneous 
B-cell hyper-responsiveness, or impaired immune regulation. Thus, the etiology 
of SLE still remains poorly understood and warrants in-depth investigation for the 
management of the disease. 
Evidences exist for the involvement of mycobacterial protein antigens in the 
pathogenesis of autoimmune disease. Furthermore, established evidences exist 
for autoimmune mediated destruction of islet cells of pancreas in the 
pathogenesis of Type-1 Diabetes mellitus for which various markers have been 
identified. 
The direct and or indirect role of proinflammatory cytokine namely TNF-a in SLE 
has been indicated. TNF-a exerting its effects through its receptors namely 
TNFR-I and TNFR-II plays a crucial role in host defense. Inhibition of TNF-a 
clearly predisposes to certain infections, such as granulomatous infections like 
TB. Inhibition of TNF-a may also play a role in autoimmunity although the 
pathophysiologic mechanisms are uncertain. Furthermore, cases of TB have 
been reported in patients treated with TNF-a-antagonists. The risk for TB in 
RA/SLE patients is associated with multiple other factors including age, country 
of origin or current residence, exposure history to persons with TB, concomitant 
therapy with other immunomodulators including corticosteroids, and disease 
activity. Focus has now shifted to development of compounds from natural 
sources that have anti-inflammatory and antimycobacterial activity. By boosting 
host immunologic responsiveness, these compounds may be particularly useful 
in the treatment of autoimmune disorders as well as drug-resistant tuberculosis. 
Our study involves the incorporation of such a compound, namely EGCG - a 
green tea polyphenol, as the natural herbal component for SLE and SLE-TB 
management. 
Thus, the present study was carried out to probe the possible involvement of 
mycobacterial protein / nucleic acid antigen{s) acting as an alternate auto antigen 
for autoimmune disorders by employing various techniques such as direct 
binding and competition ELISA, cell culture with and without modulators, 'real 
time' RT-PCR, etc. Thus, it is hoped that the present study would help in the 
better understanding about the contributory role of M. tuberculosis infection in the 
morbidity and mortality of patients with SLE. 
Cellular signalling by TNF-a is mediated mainly through activation of NF-KB. 
During characterization studies in order to assess the role of NF-KB in the 
expression of TNF-a in SLE, TB and SLE-TB monocytes, we employed SN50, an 
inhibitor of NF-KB. From our results, it was apparent that the induction of TNF-a 
expression was mediated through activation of NF-KB, because TNF- a was 
suppressed when SN50 was present in cultures. The inactive analogue of SN50 
(i. e. SN50M) did not have any effect. Thus, as previously reported in 
macrophages, this study also shows that cellular activation is associated with 
augmentation of expression of both TNF-a in monocytes of patients with SLE, TB 
and SLE-TB. 
Cell viability and potential cytotoxicity of EGCG, if any, on monocytes obtained 
from patients with SLE, TB and SLE-TB were determined for the concentrations 
(0-25 pg/ml) employed in this study using trypan blue and MTT assays, where 
viability of -98-99% was observed. Interestingly, no effect of EGCG was 
observed on human housekeeping genes like R18 rRNA, thereby demonstrating 
that the effect of EGCG was not mediated by cellular death, but rather by specific 
inhibition of expression as well as secretion of TNF-a. 
To the best of our understanding, in our characterization studies, we show for the 
first time that EGCG exerts potent anti-inflammatory effects on host mononuclear 
cells obtained from patients of SLE, TB and SLE-TB, as evidenced by a strong 
inhibition of the pro-inflammatory cytokine TNF-a. The results indicate an 
appreciable suppression in soluble TNF-a secretion with EGCG. 
TNF-a production in monocytes is regulated at multiple intracellular levels, 
beginning with transcription. Augmented expression of TNF-a mRNA and 
activation of a relevant transcription factor, NF-KB have been reported in 
monocytic cells infected with M. tuberculo!yis. Induction of TNF-a expression was 
mediated through activation of NF-KB, as evidenced by the suppression of 
secreted TNF-a protein in the presence of SN50, an inhibitor of NF-KB. On the 
contrary, SN50/M, an inactive analogue of SN50, failed to show any such effect. 
It has been well established that TNF-a induced nuclear translocation of NF-KB is 
inhibited by SN50 peptide as demonstrated in EMSA. In view of it, our data 
demonstrated that this effect involved inhibition of the NF-KB pathway induced by 
EGCG, probably by inhibiting the degradation of IKBO. The NF-KB heterodimer is 
retained in the cytoplasm in an inactive form through association with one of the 
IKBS inhibitory proteins. 
In continuation to the above, a role for the antioxidant enzyme glutathione 
peroxidase (GPx) in MTB-infected and autoimmune mononuclear cells was 
investigated with respect to various modulators employed in this study. In the 
present study, reduced / suppressed GPx activity in patient monocytes that were 
untreated or treated with SN50/M was recorded, thereby concurring with earlier 
reports that substantial amounts of ROS are being generated in patient cells due 
to cellular activation. Enhancement of GPx activity in monocyte cultures from 
patients with SLE, TB and SLE-TB after addition of NAC, a precursor of the in 
vivo antioxidant glutathione, indicates reversal of impaired neutralizing 
mechanisms. Surprisingly, GPx activity was observed to be further augmented 
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when EGCG was co-cultured instead of NAC, indicating EGCG to be an effective 
natural antioxidant combating ROS, generated as a consequence of cellular 
activation in mononuclear phagocytes. Moreover, in continuation to the above, 
our data further shows the lipid peroxidation-induced augmented MDA levels in 
culture supernatants of monocytes from patients with SLE, TB and SLE-TB were 
appreciably suppressed or down-regulated with EGCG. 
Our results are strongly indicative for the appreciable correlation between 
autoimmune diseases like SLE and Mycobacterium tuberculosis infection. 
Inhibition ELISA results strongly suggests that all the TB positive sera selected in 
this study were having a high degree of specificity towards MTB Ag85B (30kDa). 
Similarly, our data show high degree of recognition of anti-DNA antibodies found 
in SLE sera by native dsDNA. The achievement of 50% inhibition in antibody 
activity in both the above diseases i. e. TB and SLE at a very low inhibitor 
concentrations are indicative for the presence of highly specific respective 
antibodies in all the sera selected for this study. 
One of the interesting findings of this study was that the SLE patients were 
found to be more susceptible to TB development than the vice-versa case. This 
is evident from the data indicating that autoantibodies found in SLE sera strongly 
recognized both native dsDNA as well as mycobacterial Ag85B 30kDa, whereas 
anti-TB antibodies found in TB sera strongly recognized only Ag85B 30kDa, 
whereas it exhibited low or negligible recognition with native dsDNA. However, 
antibodies found in sera of patients suffering with both TB along with SLE (SLE-
TB) revealed high specificity for both the antigens i. e. native dsDNA and MTB 30 
kDa. 
An attempt was also made to evaluate the immuno-binding by generating in-vivo 
conditions i. e. by using cultured monocytes that were infected with bacilli (TB 
patients) as well as monocytes from SLE patients. The high percent maximum 
inhibitions as well 50% inhibitions in anti-TB and anti-DNA activities at extremely 
low inhibitor concentrations are suggestive for the appreciably high affinity 
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immuno-interaction occurring between anti-TB antibodies and anti-DNA 
autoantibodies with antigens in monocyte protein lysates as well as respective 
dsDNA of TB patients and SLE patients respectively. 
A striking finding in the present study is the EGCG as well as reduced 
glutathione-induced down-regulation in binding of anti-TB antibodies and anti-
DNA antibodies with antigens present in protein lysates prepared from monocyte 
of TB patients and SLE patients respectively. Similar actions of reduced 
glutathione in monocytes obtained from blood of patients having both TB along 
with SLE further substantiates the antioxidant-induced suppression in immuno-
binding. Furthermore, these results are correlating appreciably with the amount 
of TNF-a secreted in different monocyte cultures undertaken in this study. 
To have further in-sight, the present study involves utilization of dsDNA isolated 
from monocyte cultures of SLE, TB and SLE-TB patients that were either 
untreated or treated with EGCG, NAC, SN50 and SN50M, an in turn, employed 
as antigens / inhibitors in immunoassays against anti-DNA SLE antibodies and 
anti-TB antibodies respectively. Thus, interesting important observations were 
made. We observed that purified anti-DNA antibodies from SLE patients 
exhibited high degree of recognition / specificity against dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively. However, this high 
magnitude specificity / binding of purified anti-DNA antibodies from SLE patients 
was reduced or suppressed appreciably towards respective dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively that were treated 
with EGCG, NAC or SN50. On the contrary, anti-TB antibodies exhibited high 
binding only with dsDNA isolated from monocytes of patients with TB, but failed 
to show any significant recognition / binding with dsDNA isolated from monocytes 
of patients with SLE. Furthermore, when monocyte cultures of SLE, TB and 
SLE-TB patients that were treated with EGCG, NAC and SN50, and in turn, 
respective dsDNA isolated and employed in ELISA, reduced or insignificant 
binding was observed against anti-dsDNA antibodies from SLE patients or anti-
TB antibodies from TB patients. Thus, in view of the fact that native DNA is a 
poor immunogen, and that, the exact trigger of anti-DNA production in SLE still 
remains poorly understood, where DNA has been thought to act only as a cross-
reacting antigen, the results indicate possible involvement of Mycobacterium 
tuberculosis protein(s) / nucleic acid antigens(s) in providing an alternate trigger / 
origin for autoantibody production in systemic lupus erythematosus (SLE). 
Moreover, the data generated in the present study is suggestive for the fact that 
- reactive oxygen species (ROS) generated as a consequence of stress of any 
kind in autoimmune SLE results in the activation of proinflammatory cytokine 
TNF-a, \Nh\ch in turn results in the production of anti-DNA auto antibodies. These 
SLE patients having high ROS levels become highly susceptible to MTB 
infection. Upon MTB infection, the ROS and TNF-a potentiates or activates the 
MTB 85B replication in SLE-TB patients. Such an activation of ROS or TNF-a 
and in turn the SLE and TB proliferation could be arrested or limited by the usage 
of EGCG- a green tea polyphenol and reduced glutathione as revealed by our 
data. In conclusion, based on characterization studies, followed by 
immunological data, it can be inferred from the present study that: 
1. There exist high basal levels of TNF-a in sera as well as in monocyte 
cultures of patients with SLE, TB and SLE-TB. 
2. Activation of monocytes by M. tuberculosis infection in SLE patients 
induces the expression of both TNF-a at both the gene and protein levels. 
3. Both RNI and ROI, induced early after infection of SLE monocytes, 
increases expression of TNF-a. 
4. Activation of monocytes by M. tuberculosis initiates a cascade of events 
whereby a vicious circle may exist in which expression of host 
inflammation and mycobacterial products amplify one another. 
5. EGCG (0-25 pg/ml) exhibited no toxic effect on the viability of human 
monocytes. 
6. EGCG inhibits the expression of TNF-a protein production in a dose-
dependent manner in 24 hr monocyte cultures from patients with SLE, TB 
and SLE-TB, and that, it is mediated mainly via NF-KB. 
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7. EGCG ameliorates the glutathione peroxidase activity in monocytes from 
patients with SLE, TB and SLE-TB. 
8. EGCG suppresses the augr..ented MDA levels in monocytes from patients 
with SLE. TB and SLE-TB. 
9. All the M. tuberculosis and SLE sera involved in this study showed a high 
degree of specificity for Ag85B (30 kDa) and native dsDNA respectively. 
10. Mycobacterial 30 kDa protein antigen (Ag85B) as well as protein lysates 
prepared from monocytes of M. tuberculosis patients were recognized 
appreciably by anti-tuberculosis antibodies present in M. tuberculosis 
sera, whereas non-mycobacterial native ds.DNA showed poor recognition 
with the same anti-tuberculosis antibodies. 
11. On the contrary, both non-mycobacterial native dsDNA and protein lysates 
prepared from monocytes of SLE patients as well as mycobacterial 30 
kDa protein antigen (Ag85B) were found to be recognized appreciably by 
anti-DNA autoantibodies present in SLE sera. 
12. Furthermore, co-culturing of monocytes obtained from M. tuberculosis, 
SLE or M. tuberculosis-SLE with 10 nM of reduced glutathione showed 
amelioration of ROS and TNF-a induced actions, which in turn, 
subsequently suppressed the immuno-bindings observed in monocytes of 
M. tuberculosis and SLE patients cultured without glutathione. 
13. Our data shows that SLE patients are more susceptible to M. tuberculosis 
development, as ROS and TNF-a in SLE patients could activate the 
replication of AgSSB (30 kDa) after bacilli infection. 
14. Finally, immunoaffinity purified anti-DNA antibodies from SLE patients 
recognized dsDNA isolated from monocytes of both SLE and TB patients, 
but on the contrary, anti-TB antibodies recognized dsDNA only from 
monocytes from TB patients but not SLE patients. 
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Abstract 
One of the hallmarks of Immune system is the tremendous potentiality to 
discriminate between self and non-self. Systemic Lupus Erythematosus (SLE) - a 
prototype autoimmune disorder, is a chronic, life-long and potentially fatal 
disease, which is characterized by unpredictable exacerbations and remissions 
with protean clinical manifestations. SLE is a complex disorder affecting 
predominately ycung populations and shares similarities with HIV infection which 
is well known associated with tuberculosis (HIV-Tuberculosis) as regards the 
propensity for multiple organ involvement, potentially life-threatening episodes, 
and need for sophisticated monitoring. The clinical features of SLE are protean 
and may mimic infectious mononucleosis, lymphoma, or other systemic disease. 
The origin of autoantibody production in SLE is still poorly understood till date. 
However, a role has been suggested for an antigen driven process, spontaneous 
B-cell hyper-responsiveness, or i.npaired immune regulation. Thus, the etiology 
of SLE still remains poorly understood and warrants in-depth investigation for the 
management of the disease. 
Evidences exist for the involvement of mycobacterial protein antigens in the 
pathogenesis of autoimmune disease. Furthermore, established evidences exist 
for autoimmune mediated destruction of isiet cells of pancreas in the 
pathogenesis of Type-1 Diabetes melli'us for which various markers have been 
identified. 
The direct and or indirect role of proinflammatory cytokine namely TNF-a in SLE 
has been indicated. TNF-a exerting its effects through its receptors namely 
TNFR-I and TNFR-II plays a crucial role in host defense. Inhibition of TNF-a 
clearly predisposes to certain infections, such as granulomatous infections like 
TB. Inhibition of TNF-a may also play a role in autoimmunity although the 
pathophysiologic mechanisms are uncertain. Furthermore, cases of TB have 
been reported in patients treated with TNF-a-antagonists. The risk for TB in 
RA/SLE patients is associated with multiple other factors including age. country 
of origin or current residence, exposure history to persons with TB, concomitant 
therapy with other immunomodulators including corticosteroids, and disease 
activity. Focus has now shifted to development of compounds from natural 
sources that have anti-inflsmmatory and antimycobacterial activity. By boosting 
host immunologic responsiveness, these compounds may be particularly useful 
in the treatment of autoimmune disorders as well as drug-resistant tuberculosis. 
Our study involves the incorporation of such a compound, namely EGCG - a 
green tea polyphenol, as the natural herbal component for SLE and SLE-TB 
management. 
Thus, the present study was carried out to probe the possible involvement of 
mycobacterial protein / nucleic acid antigen(s) acting as an alternate auto antigen 
for autoimmune disorders by employing various techniques such as direct 
binding and competition ELISA, cell culture with and without modulators, 'real 
time' RT-PCR, etc. Thus, it is hoped that the present study would help in the 
better understanding about the contributory role of M. tuberculosis infection in the 
morbidity and mortality of patients with SLE. 
Cellular signalling by TNF-a is mediated mainly through activation of NF-KB. 
During characterization studies in order to assess the role of NF-KB in the 
expression of TNF-a in SLE, TB and SLE-TB monocytes, we employed SN50, an 
inhibitor of NF-KB. From our results, it was apparent that the induction of TNF-a 
expression was mediated through activation of NF-KB, because TNF- a was 
suppressed when SN50 was present in cultures. The inactive analogue of SN50 
(i. e. SN50M) did not have any effect. Thus, as previously reported in 
macrophages, this study also shows that cellular activation is associated with 
augmentation of expression of both TNF-a in monocytes of patients with SLE, TB 
and SLE-TB. 
Cell viability and potential cytotoxicity of EGCG, if any, on monocytes obtained 
from patients with SLE, TB and SLE-TB were determined for the concentrations 
(0-25 |jg/ml) employed in this study using trypan blue and MTT assays, where 
viability of ~98-99% was observed. Interestingly, no effect of EGCG was 
observed on human housekeeping genes like R18 rRNA, thereby demonstrating 
that the effect of EGCG was not mediated by cellular death, but rather by specific 
inhibition of expression as well as secretion of TNF-a. 
To the best of our understanding, in our characterization studies, we show for the 
first time that EGCG exerts potent anti-inflammatory effects on host mononuclear 
cells obtained from patients of SLE, TB and SLE-TB, as evidenced by a strong 
inhibition of the pro-inflammatory cytokine TNF-a. The results indicate an 
appreciable suppression in soluble TNF-a secretion with EGCG. 
TNF-a production in monocytes is regulated at multiple intracellular levels, 
beginning with transcription. Augmented expression of TNF-a mRNA and 
activation of a relevant transcription factor, NF-KB have been reported in 
monocytic cells infected with M. tuberculosis. Induction of TNF-a expression was 
mediated through activation of NF-KB, as evidenced by the suppression of 
secreted TNF-a protein in the presence of SN50, an inhibitor of NF-KB. On the 
contrary, SN50/M, an inactive analogue of SN50, failed to show any such effect. 
It has been well established that TNF-a induced nuclear translocation of NF-KB is 
inhibited by SN50 peptide as demonstrated in EMSA. In view of it, our data 
demonstrated that this effect involved inhibition of the NF-KB pathway induced by 
EGCG, probably by inhibiting the degradation of IKBO. The NF-KB heterodimer is 
retained in the cytoplasm in an inactive form through association with one of the 
IKBS inhibitory proteins. 
In continuation to the above, a role for the antioxidant enzyme glutathione 
peroxidase (GPx) in MTB-infected and autoimmune mononuclear cells was 
investigated with respect to various modulators employed in this study. In the 
present study, reduced / suppressed GPx activity in patient monocytes that were 
untreated or treated with SNSO/M was recorded, thereby concurring with earlier 
reports that substantial amounts of ROS are being generated in patient cells due 
to cellular activation. Enhancement of GPx activity in monocyte cultures from 
patients with SLE, TB and SLE-TB after addition of NAC, a precursor of the in 
vivo antioxidant glutathione, indicates reversal of impaired neutralizing 
mechanisms. Surprisingly, GPx activity ".-35 observed to be further augmented 
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when EGCG was co-cultured instead of NAC, indicating EGCG to be an effective 
natural antioxidant combating ROS, generated as a consequence of cellular 
activation in mononuclear phagocytes. Moreover, in continuation to the above, 
our data further shows the lipid peroxidation-induced augmented MDA levels in 
culture supernatants of monocytes from patients with SLE, TB and SLE-TB were 
appreciably suppressed or down-regulated with EGCG. 
Our results are strongly indicative for the appreciable correlation between 
autoimmune diseases like SLE and Mycobacterium tuberculosis infection. 
Inhibition ELISA results strongly suggests that all the TB positive sera selected in 
this study were having a high degree of specificity towards MTB Ag85B (30kDa). 
Similarly, our data show high degree of recognition of anti-DNA antibodies found 
in SLE sera by native dsDNA. The achievement of 50% inhibition In antibody 
activity in both the above diseases i. e. TB and SLE at a very low inhibitor 
concentrations are indicative for the presence of highly specific respective 
antibodies in all the sera selected for this study. 
One of the interesting findings of this study was that the SLE patients were 
found to be more susceptible to TB development than the vice-versa case. This 
is evident from the data indicating that autoantibodies found in SLE sera strongly 
recognized both native dsDNA as well as mycobacterial Ag85B 30kDa, whereas 
anti-TB antibodies found in TB sera strongly recognized only Ag85B 30kDa, 
whereas it exhibited low or negligible recognition with native dsDNA. However, 
antibodies found in sera of patients suffering with both TB along with SLE (SLE-
TB) revealed high specificity for both the antigens i. e. native dsDNA and MTB 30 
kDa. 
An attempt was also made to evaluate the immuno-binding by generating in-vivo 
conditions i. e. by using cultured monocytes that were infected with bacilli (TB 
patients) as well as monocytes from SLE patients. The high percent maximum 
inhibitions as well 50% inhibitions in anti-TB and anti-DNA activities at extremely 
low inhibitor concentrations are suggestive for the appreciably high affinity 
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immuno-interaction occurring between anti-TB antibodies and anti-DNA 
autoantibodies with antigens in monocyte protein lysates as well as respective 
usDNA of TB patients and SLE patients respectively. 
A striking finding in the present study is the EGCG as well as reduced 
glutathione-induced down-regulation in binding of anti-TB antibodies and anti-
DNA antibodies with antigens present in protein lysates prepared from monocyte 
of TB patients and SLE patients respectively. Similar actions of reduced 
glutathione in monocytes obtained from blood of patients having both TB along 
with SLE further substantiates the antioxidant-induced suppression in immuno-
binding. Furthermore, these results are correlating appreciably with the amount 
of TNF-a secreted in different monocyte cultures undertaken in this study. 
To have further in-sight, the present study involves utilization of dsDNA isolated 
from monocyte cultures of SLE, TB and SLE-TB patients that were either 
untreated or treated with EGCG, NAC, SN50 and SN50M, an in turn, employed 
as antigens / inhibitors in immunoassays against anti-DNA SLE antibodies and 
anti-TB antibodies respectively. Thus, interesting important observations were 
made. We observed that purified anti-DNA antibodies from SLE patients 
exhibited high degree of recognition / specificity against dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively. However, this high 
magnitude specificity / binding of purified anti-DNA antibodies from SLE patients 
was reduced or suppressed appreciably towards respective dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively that were treated 
with EGCG, NAC or SN50. On the contrary, anti-TB antibodies exhibited high 
binding only with dsDNA isolated from monocytes of patients with TB, but failed 
to show any significant recognition / binding with dsDNA isolated from monocytes 
of patients with SLE. Furthermore, when monocyte cultures of SLE, TB and 
SLE-TB patients that were treated with EGCG, NAC and SN50, and in turn, 
respective dsDNA isolated and employed in ELISA, reduced or insignificant 
binding was observed against anti-dsDNA antibodies from SLE patients or anti-
TB antibodies from TB patients. Thus, in view of the fact that native DNA is a 
poor immunogen, and that, the exact trigger of anti-DNA production in SLE still 
remains poorly understood, where DNA has been thought to act only as a cross-
reacting antigen, the results indicate possible involvement of Mycobacterium 
tuberculosis prctein(s) / nucleic acid antigens(s) in providing an alternate trigger / 
origin for autoantibody production in systemic lupus erythematosus (SLE). 
Moreover, the data generated in the present study is suggestive for the fact that 
- reactive oxygen species (ROS) generated as a consequence of stress of any 
kind in autoimmune SLE results in the activation of proinflammatory cytokine 
TNF-a, which in turn results in the production of anti-DNA auto antibodies. These 
SLE patients having high ROS levels become highly susceptible to MTB 
infection. Upon MTB infection, the ROS and TNF-a potentiates or activates the 
MTB 85B replication in SLE-TB patients. Such an activation of ROS or TNF-a 
and in turn the SLE and TB proliferation could be arrested or limited by the usage 
of EGGG- a green tea polyphenol and reduced glutathione as revealed by our 
data. In conclusion, based on characterization studies, followed by 
immunological data, it can be inferred from the present study that; 
1. There exist high basal levels of TNF-a in sera as well as in monocyte 
cultures of patients with SLE, TB and SLE-TB. 
2. Activation of monocytes by M. tuberculosis infection in SLE patients 
induces the expression of both TNF-a at both the gene and protein levels. 
3. Both RNI and ROI, induced early after infection of SLE monocytes, 
increases expression of TNF-a. 
4. Activation of monocytes by M. tuberculosis initiates a cascade of events 
whereby a vicious circle may exist in which expression of host 
inflammation and mycobacterial products amplify one another. 
5. EGGG (0-25 pg/ml) exhibited no toxic effect on the viability of human 
monocytes. 
6. EGGG inhibits the expression of TNF-a protein production in a dose-
dependent manner in 24 hr monocyte cultures from patients with SLE, TB 
and SLE-TB, and that, it is mediated mainly via NF-KB. 
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7. EGCG ameliorates the glutathione peroxidase activity in monocytes from 
patients with SLE, TB and SLE-TB. 
8. E3CG suppresses the augmented MDA levels in monocytes from patients 
with SLE, TB and SLE-TB. 
9. All the M. tuberculosis and SLE sera involved in this study showed a high 
degree of specificity for Ag85B (30 kDa) and native dsDNA respectively. 
10. Mycobacterial 30 kDa protein antigen (Ag85B) as well as protein lysates 
prepared from monocytes of M. tuberculosis patients were recognized 
appreciably by anti-tuberculosis antibodies present in M. tuberculosis 
sera, whereas non-mycobacterial native dsDNA showed poor recognition 
with the same anti-tuberculosis antibodies. 
11. On the co.ntrary, both non-mycobacterial native dsDNA and protein lysates 
prepared from monocytes of SLE patients as well as mycobacterial 30 
kDa protein antigen (Ag85B) were found to be recognized appreciably by 
anti-DNA autoantibodies present in SLE sera. 
12. Furthermore, co-culturing of monocytes obtained from M. tuberculosis, 
SLE or M. tuberculosis-SLE with 10 nM of reduced glutathione showed 
amelioration of ROS and TNF-a induced actions, which in turn, 
subsequently suppressed the immuno-bindings observed in monocytes of 
M. tuberculosis and SLE patients cultured without glutathione. 
13. Our data shows that SLE patients are more susceptible to M. tuberculosis 
development, as ROS and TNF-a in SLE patients could activate the 
replication of Ag85B (30 kDa) after bacilli infection. 
14. Finally, immunoaffinity purified anti-DNA antibodies from SLE patients 
recognized dsDNA isolated from monocytes of both SLE and TB patients, 
but on the contrary, anti-TB antibodies recognized dsDNA only from 
monocytes from TB patients but not SLE patients. 
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INTRODUCTION 
The central dogma of immunolCay for many years was focused on the dona! 
detection of auto reactive cells, thereby, leaving a repertoire of T cells that 
recognize specific foreign antigen. However, with the advancement in the field of 
immunology, it was acknowledged that a low level of autoreactivity is physiologic 
(Dighiero et al., 1999) and crucial to normal immune function. Autoantigen helps 
to form the repertoire of mature lymphocytes, and the survival of naive T cells 
(Goldrath et al., 1999) and B cells (Gu et al., 1991) in the periphery requires 
continuous exposure to auto antigens. Since there is no fundamental difference 
between the structure of self antigens (auto antigens) and that of foreign 
antigens, lymphocytes evolved not to distinguish self from foreign, as some have 
speculated, but to respond to antigen only in certain microenvironments, 
generally in the presence of inflammatory cytokines (Silverstein et al., 2000). 
Since autoreactivity is physiologic, the challenge is to understand how it 
becomes a pathologic process and how T cells and B cells contribute to tissue 
injury. 
One of the hallmarks of immune system is the tremendous potentiality to 
discriminate between self and non-self. However, this enormous recognition 
potential includes possible interaction with self components, some of which may 
appear to be essential for the regulation of the immune functions whereas others 
can be pathogenic, particularly if expressed at high level, leading to autoimmune 
diseases. 
Systemic Lupus Erythematosus (SLE) - a prototype autoimmune disorder, is a 
chronic, life-long and potentially fatal disease, which is characterized by 
unpredictable exacerbations and remissions with protean clinical manifestations. 
In SLE, there is a predilection for clinical involvement of the joints, skin, kidney, 
brain, serosa, lung, heart and gastrointestinal tract. Moreover, SLE is a complex 
disorder affecting predominately young populations and shares similarities with 
HIV infection which is well known associated with tuberculosis (HIV-
Tuberculosis) as regards the propensity for mjltipie organ involvement, 
potentially life-threatening episodes, and need for sophisticated monitoring. The 
clinical features of SLE are protean and may mimic infectious mononucleosis, 
lymphoma, or other systemic disease. The origin of autoantibody production in 
SLE is still poorly understood till date. However, a role has been suggested for 
an antigen driven process, spontaneous B-cell hyper-responsiveness, or 
impaired immune regulation. Thus, the etiology of SLE still remains poorly 
understood and warrants in-depth investigation for the management of the 
disease. 
Evidences exist for the involvement of mycobacterial protein antigens in the 
pathogenesis of autoimmune disease (Tasneem et al., 2001). Furthermore, 
established evidences exist for autoimmune mediated destruction of islet cells of 
pancreas in the pathogenesis of Type-1 Diabetes mellitus for which various 
markers have been identified. 
The direct and or indirect role of proinflammatory cytokine namely TNF-a in SLE 
has been indicated. TNF-a exerting its effects through its receptors namely 
TNFR-I and TNFR-II is a central mediator of inflammation, immunity and 
autoimmunity and that, it plays a crucial role in host defense. Inhibition of TNF-a 
clearly predisposes to certain infections, such as granulomatous infections like 
TB (Islam et al., 2004; Wilkinson et al., 2001). Inhibition of TNF-a may also play a 
role in autoimmunity although the pathophysiologic mechanisms are uncertain. 
Furthermore, cases of TB have been reported in patients treated with TNF-a-
antagonists. The risk for TB in RA/SLE patients is associated with multiple other 
factors including age, country of origin or current residence, exposure history to 
persons with TB, concomitant therapy with other immunomodulators including 
corticosteroids, and disease activity. TNF-a antagonists have been associated 
with an increase in the percentage of RA patients with positive serologies (ANA 
and anti-ds-DNA) and lupus-like syndromes. It is to be pointed out that the role of 
TNF-a in patients with osteoarthritis, which is an important form of arthritis as 
wel! as novel therapeutic strategies for the management of osteoarthritis has 
been well documented (Islam et al., 2002; Malemud et al., 2003). 
In view of the above, the present study was carried out to probe the possible 
involvement of mycobacterial protein / nucleic acid antigen(s) acting as an 
alternate auto antigen for autoimmune disorders by employing various 
techniques such as SDS-PAGE, direct binding and competition ELISA, cell 
culture with and without modulators, 'real time" RT-PCR, etc. Thus, it is hoped 
that the present study would help in the better understanding about the 
contributory role of M. tuberculosis infection in the morbidity and mortality of 
patients with SLE. 
AUTOIMMUNE DISORDERS AND ITS BASIS 
For clinicians, autoimmune diseases appgar to be either systemic (as in the case 
of systemic lupus erythematosus) or organ-specific (as in the case of type 1 
diabetes mellitus). This classification, although clinically useful, does not 
necessarily correspond to a difference in causation. Alterations that lower the 
threshold for the survival and activation of autoreactive B cells, often cause the 
production of multiple autoantibodies, as in the case of the antinuclear and anti-
DNA antibodies in systemic lupus erythematosus (Gorelik et al., 2000; Majeti et 
al., 2000). Genetic alterations with global effects on the function of regulatory T 
cells or cytokine production often lead to inflammatory bowel disease. (Bhan et 
al., 1999; Blumberg et al., 1999; Boismenu and Chen, 2000). 
Environmental Triggers 
Even in a genetically predisposed person, some trigger - an environmental 
exposure or a change in the internal environment - is usually required for frank 
auto reactivity. Studies of genetically similar populations living in different 
conditions strongly suggest the importance of environmental triggers. For 
example, the incidence of both type 1 diabetes and multiple sclerosis in a 
population changes as the members migrate to different regions (Noseworthy et 
al., 2000; Dahlquist, 1998). 
Infectious Agents 
Microbial antigens liave thie potential to initiate autoreactivity through molecular 
mimicry, polyclonal activation, or the release cf previously sequestered antigens, 
for example, in autoimmune diabetes, T cells recognize both a peptide derived 
from the autoantigen glutamic acid dcecarboxylase and a highly analogous 
peptide from coxsackievirus P2-C protein (Kukreja et al., 2000). 
Microbial infection can also cause polyclonal activation of autoreactive 
lymphocytes. This is presumed to be the mechanism underlying the increased 
incidence of autoimmune disease in rodents exposed to microbial pathogens 
(Horwitz et al., 1998). Microbes that kill cells can cause inflammation, release of 
sequestered antigens, resulting in autoimmunity (Honwitz et al., 1998; Miller et 
al., 1997). 
Noninfectious Triggers 
Many autoimmune diseases are much common in women than in men, and 
estrogens exacerbate systemic lupus erythematosus in murine models of the 
disease by altering the B-cell repertoire in the absence of inflammation (Bynoe et 
al., 2000). There is mounting evidence that blockade of TNF-a, which is 
beneficial in Crohn's disease and rheumatoid arthritis, can induce antinuclear 
antibodies and perhaps even systemic lupus erythematosus and multiple 
sclerosis in certain persons (Charles et al., 2000; Mohan et al., 2000). TNF-a has 
inhibitory effects on activated T cells, (Cope et al., 1997; Kassiotis and Kollias, 
2001), but how it induces autoimmunity is unknown. 
Loss of Regulatory Cells 
Several kinds of regulatory cells are important in controlling autoreactivity: CD1-
restricted T cells, T cells with / receptors, CD4+CD25+ T cells, and T cells that 
produce cytokines that suppress pathogenic autoreactive cells. Some of these 
regulatory cells - for example, CD4+CD25+ T cells - must mature in the thymus 
(Shevach, 2000); others require activation by autoantigens in the periphery. 
Alterations in the number and function of regulatory cells may contribute to 
autoimmunization. In monozygotic twins who are discordant for diabetes, for 
instance, levels of CD1-restricted T cellc are greatly diminished in the affected 
twin (Wilson et al., 1998). 
DISEASE PROGRESSION 
Epitope Spreading 
As an autoimmune disease progresses from initial activation to a chronic state 
there is often an increase in the number of autoantigens targeted by T cells and 
antibodies ("epitope spreading") (Moudgil and Sercarz, 1994; Lanzavecchia, 
1995), and, in some cases, a change in participating cells, cytokines, and other 
inflammatory mediators. Both autoreactive T cells and B cells contribute to 
epitope spreading. 
Pathogenic Mechanisms 
It has become apparent, primarily through studies in animals, that different 
effector cells and inflammatory mediators as the disease progresses may 
supersede the initial mechanisms causing autoreactivity in an autoimmune 
disease. NaTve lymphocytes are activated at the initiation of disease and may 
continue to be recruited by epitope spreading later in the disease, but it is 
unknown whether naive cells or memory cells cause progression and flares of 
disease. 
The fact that the cells and soluble mediators of injury can change over time has 
tremendous implications for therapy; interventions that are effective early may be 
less efficacious later on or may even be harmful. The unpredictability of these 
effects is amply illustrated by the clinical efficacy of the blockade of TNF-a in 
rheumatoid arthritis and Crohn's disease, at the cost of including antinuclear 
antibodies in up to 10 percent of treated patients and systemic lupus 
erythbematosus in a few patients. 
Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus (SLE) is defined by its clinical features and by 
the almost invariable presence of antibodies in blood / sera, directed against one 
or more components of cell nuclei. Certain manifestations seem to be associated 
with the presence of different antinuclear antibodies and genetic markers, which 
suggests that SLE may be a family of diseases. However, clinical presentations 
frequently overlap, and there is currently no conclusive evidence that SLE is 
more than a single disorder with a broad range of manifestations, the expression 
of which may be influenced by the patient's genetic background. Occasionally 
patients have features of both SLE and other connective-tissue diseases, such as 
rheumatoid arthritis and scleroderma. 
Antinuclear antibodies have not been shown to be directly involved in the 
pathogenesis of the disease, but patients with SLE often have other circulating 
antibodies that react with cell membranes or serum components. Some are 
directly responsible for clinical manifestations; others may play a part in the 
immune dysregulation that underlies the disease. The mechanisms that result in 
such prolific antibody production are a focus of intense research. 
The prevalence of SLE varies throughout the world. In North America and 
northern Europe, it is about 40 per 100,000 population (Hochberg, 1990). Over 
80 percent of cases occur in women during their childbearing years. As a 
consequence, the disease may affect as many as 1 in 1000 young women. The 
prevalence in children and older adults is approximately 1 per 100,000, with a 
ratio of female to male patients of 3:1. 
Diagnosis 
Polyarthritis and dermatitis are the most common clinical manifestations of SLE, 
and the most common presenting symptoms (Pistiner et al., 1991). However, any 
symptom or sign of the disease may be its first manifestation, and a single one, 
such as arthritis, thrombocytopenia, or pericarditis, may persist or recur for 
months or years before the diagnosis can be confirmed by the appearance of 
other features. Chronic fatigue and a variety of disturbances of cognition or affect 
including anxiety and depression are frequently described by patients as early 
symptoms (Iverson, 1993). Isolated major involvement of the kidney or central 
nervous system is unusual. Criteria to distinguish SLE from other connective-
tissue diseases have been established by the American Rheumatism Association 
and were revised in 1982 and 1997 (Tan et al., 1982; Hochberg, 1997). 
The detection of antinuclear antibodies is a sensitive screening test for SLE. 
Since antinuclear antibodies occur in more than 95 percent of patients, 
(Hochberg, 1990) it is hard to be certain of the diagnosis in their absence. The 
most common antibody in patients with the disease is directed against 
nucleosomal DNA-histone complexes, and it yields a homogeneous staining 
pattern on the immunofluorescence test for antinuclear antibodies (Mohan et al., 
1993). Antinuclear antibody also occurs in most of the other rheumatic diseases, 
autoimmune liver and thyroid diseases, and some drug reactions (Tan, 1989). It 
is produced transiently in viral infections and is present, usually in low titers, in 
about 2 percent of the normal population. The degree of positivity of the anti-
nuclear-antibody test is diagnostically important. Serum dilutions below which 
normal serum may be positive for these antibodies vary in different laboratories. 
Titers that are less than two times higher than the normal limit in any laboratory 
should be viewed skeptically. The positive predictive value of the test increases 
with higher titers. 
Antibodies to native or double-stranded DNA and to Sm, a ribonuclear protein 
antigen, are more specific than other antinuclear antibodies for the diagnosis of 
SLE. Their presence does not predict particular disease manifestations, although 
nephritis is more common in patients with antinative DNA (Swaak et al., 1986). 
For many of the patients who have anti-native DNA, the titer of this antibody is a 
useful measure of disease activity (Borg et al., 1990). 
Clinical Course of SLE 
The natural history of SLE is highly variable and unpredictable. The 10-year 
survival rate for patients observed over the past decade approaches 90 percent 
(Pistiner et al., 1991). The presence of nephritis and systolic hypertension 
indicates a poorer prognosis (Seleznick and Fries, 1991). The risk of life-
threatening complications, particularly nephritis, appears to be greater during the 
first five years after the onset of the disease and is associated with the presence 
of antibody to native DNA and younger age (Swaak et a!., 1989). The prognosis 
for men and children with SLE is less favorable than it is for women (Miller et al., 
1983; Barron et al., 1993). SLE that begins in either sex after the age of 60 tends 
to have a more benign course; arthritis, pleurisy, rash, and anemia are usually the 
major manifestations (Baker et al., 1979). 
Antiphospholipid antibody can be detected in approximately 30 percent of 
patients with SLE (Love and Santoro, 1990). It is responsible for a wide variety of 
thromboembolic complications, such as stroke, portal-vein thrombosis, 
thrombophlebitis, and pulmonary embolism (McHugh et al., 1991). For these 
reasons, it is an important determinant of disease outcome (Lockshin, 1993). The 
risk of thromboembolic complications is not the same for all patients who have 
antiphospholipid antibody, and no single test to detect the antibodies can reliably 
predict the risk. The risk seems to be greater in patients who have positive results 
on one of the tests assessing function, such as the diluted-thromboplastin time. A 
recently identified cofactor may be important (Ordi et al., 1993). Acute infections 
can lead to a positive result on immunoassay that is not dependent on the 
cofactor. 
NATURAL HISTORY OF TUBERCULOSIS 
Agent factors 
M. tuberculosis is a facultative intracellular parasite, it is readily ingested by 
phagocytes and is resistant to intracellular killing. Of importance to man are the 
human and bovine strains. The human virulent strain (HayRv) is responsible for 
the vast majority of cases. The bovine strain affects mainly cattle and other 
animals. Regarding virulence, the Indian tubercle bacillus is said to be less 
virulent than the European bacillus. In recent year, a number of mycobacteria 
have been isolated from human which have been classified into 4 groups - (i) 
photocromogens (e.g. M. Kansasii); (ii) scotociiromogens (e.g. M. scrofulaceum); 
(iii) non-photocromogens (e.g. M. intercellular) and (iv) rapid growers (e.g. M. 
fortuitum). All these are mainly saprophytic. Diseases attributed to them have 
resembled pulmonary tuberculosis and chronic cervical lymphadenitis. Non-
specific infections have been reported to be widely prevalent in the southern part 
of India (Park, 2005). 
Source of Infection: There are two sources of infection; human and bovine, 
(i) Human source: The most common source of infection is the human 
case whose sputum is positive for tubercle bacilli and who has either 
received no treatment or partially treated, 
(ii) Bovine source: The bovine source of infection is usually infected milk. 
Communicability: Patients are infected as long as they remain untreated. 
Host factors: 
Age: Tuberculosis affects all ages. In the developed countries, the disease is 
more common in the elderly. 
Sex: More prevalent in males than females. 
Heredity: Tuberculosis is not a heredity disease. However twin studies indicate 
that inherited susceptibility is an important risk factor. 
Nutrition: Malnutrition is widely believed to predisposed to tuberculosis, but the 
available evidence on this point is only indirect. 
Immunity: Man has no inherited immunity against tuberculosis. It is acquired as 
result of natural infection or BCG vaccination. 
Social Factors 
Tuberculosis is a social disease with medical aspects. It has also being 
described as a barometer of social welfare. The social factors include many non 
medical factors such as poor quality of life, poor housing and over crowding, 
population explosion, lack of education etc. (Park, 2005). 
Mode of Transmission 
Tuberculosis is transmitted mainly by droplet infection and droplet nuclei 
generated by sputum positive patients with pulmonary tuberculosis. 
Incubation Period 
The time from receipt of infection to the development of a positive tuberculin test 
ranges from 3 - 6 weeks and thereafter, the development of disease depends 
upon the closeness of contact, extent of the disease and sputum positivity of the 
source case and host parasite relationship (Park, 2005). 
Cytokine production driven by M. tuberculosis: 
Cytokines are a group of hormone-like polypeptides that play a variety of 
regulatory roles in host defense against infection. Once infection is established, a 
focal nonspecific inflammatory response follows. This response is regulated by a 
network of pro- and anti-inflammatory cytokines and chemokines (Crevel et al., 
2002), which serve as signals of infection (Means et al., 1999). There are two 
kinds of cytokines, pro-inflammatory and anti-inflammatory. The pro-inflammatory 
cytokine network plays a crucial role in the inflammatory response and the 
outcome of mycobacterial function. This response is antagonized by anti-
inflammatory mechanisms. In addition some cytokines may inhibit the production 
or the effects of pro-inflammatory cytokines in tuberculosis (Crevel et al., 2002). 
(a) Pro-inflammatory cytokines: 
(i) TNF-a: 
Stimulation of monocytes, macrophages and dendritic cells with mycobacteria or 
mycobacterial products induces TNF-a production (Henderson et al., 1997; 
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Valone et al., 1988). This prototype proinflammatory cytokine plays a key role in 
granuloma formation (Senaldi et al., 1996), induces macrophage activation and 
has immunoregulatory properties (Tsenova et a!., 1939). However, systemic 
spillover of TNF-a may account for unwanted inflammatory effects like fever and 
wasting (Crevel et al., 2002). Thus, TNF-a has both adverse and beneficial 
effects in the human immune response (Tufariello et al., 2003). To limit the 
deleterious effects of TNF-a (Hernandez and Rook, 1994; Bekker et al., 2000), 
systemic production of TNF-a is downregulated (Friedland et al., 1995; 
Takashima et al., 1990). In spite of this, anti-TNF-a therapy in the treatment of 
tuberculosis is associated with an increased risk of developing tuberculosis 
(Keane and Gershon, 2002), mainly due to reactivation of a chronic infection 
(Keane et al., 2001). In addition, TNF-a has an important role in the maintenance 
of the granulomatous response in latent tuberculosis, and in maintaining the 
organization of the granuloma, the integrity of which contributes to the 
containment of M. tuberculosis (Tufariello et al., 2003). 
(li)IL-1p: 
IL-1(3, a pro-inflammatory cytokine is produced mainly by monocytes, 
macrophages and dendritic cells (Dahl et al., 1996; Gerosa et al., 1999). It is 
expressed in excess (Schauf et al., 1993) and at the site of disease in 
tuberculosis patients (Bergeron et al., 1997). IL-1R antagonist (IL-IRa) is the 
naturally occurring antagonist of IL-1. It has been suggested that an increased IL-
ip/IL-1Ra ratio protects against a more severe presentation of tuberculosis, 
especially tuberculosis pleuritis (Wilkinson et al., 1999). 
(iii) IL-6: 
This is an early cytokine, which has both pro- and anti-inflammatory properties 
(VanHeyningen et. al., 1997) and is produced at the site of infection (Hoheisel et 
al., 1998). IL-6 may be harmful in mycobacterial infections, as it inhibits the 
production of TNF-a and IL-1 (3 (Schindler et al., 1990). However, other reports 
indicate a protective role for IL-6, which seems related to optimal IFN-y 
production early in M, tuberculosis infection (Ladel et al., 1997a). 
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(iv)IL-12: 
Mainly phagocytic cells produce IL-12 after phagocytosis of M. tuberculosis 
(Ladel at al., 1997b). It is an important early pro-inflammatory cytokine that drives 
the production of IFN-y trom natural killer (NK) cells (Trinchieri, 2003). Thus, IL-
12 is the inducer cytokine and IFN-y is the effector cytokine that mediates 
protection (Ismail et al., 2002) as discussed further. IL-12 is a regulatory cytokine 
that connects the innate and adaptive host response to mycobacteria (Trinchieri, 
1995) and which exerts its protective effects mainly through the induction of IFN-
Y (Cooper et al., 1997). In tuberculosis, IL-12 has been detected in lung infiltrates 
(Taha et al., 1997), and in granulomas (Bergeron et al., 1997). The expression of 
IL-12 receptors is also increased at the site of disease (Zhang et al., 1999). 
Three additional cytokines with IL-12-like activities have been identified, notably 
IL-18, IL-23 and IL-27 (Vosse et al., 2004). IL-18, a novel pro-inflammatory 
cytokine shares many features with IL-1 (Dinarello et al., 1998) and acts as an 
IFN-y inducing factor, synergistic with IL-12 (O'Neill and Greene, 1998). It also 
stimulates the production of other pro-inflammatory cytokines, chemokines, and 
transcription factors (Netea et al., 2000). IL-15 is similar to IL-2 in its biological 
activities and stimulates T cell and NK cell proliferation and activation (Kennedy 
and Park, 1996). However, unlike IL-2, the production of IL-15 is mainly by 
monocytes and macrophages (Crevel et al., 2002). 
(V) IFN-Y: 
An important macrophage-activating molecule involved in the immune defense 
against pathogenic mycobacteria is interferon-y. Production of IFN-y is regulated 
by other cytokines, particularly IL-12. In the early phase of the immune response, 
IL-12 drives the production of IFN-Y from NK cells (Trinchieri, 2003). Several 
immune mechanisms, such as antigen presentation, leukocyte-endothelium cell 
interactions, cell growth and apoptosis, reactive nitrogen and oxygen 
intermediates as well as phagosome-lysosome fusion can be modulated through 
the activity of IFN-y (Houben et al., 2006). Activation of macrophages by IFN-y 
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also induces autophagy, which is a normal degradative pathway implicated in 
innate immune mechanisms against M. tuberculosis (Ogawa et al., 2005). 
(b) Anti-Inflammatory cytokines: 
The pro-inflammatory response is antagonized by anti-inflammatory 
mechanisms. Soluble cytokine receptors prevent binding of cytokines to cellular 
receptors, blocking further signalling (Crevel et al., 2002). Anti-inflammatory 
cytokines are also important In immuno-regulation. 
(1) IL-10: 
IL-10 is produced by macrophages after M. tuberculosis phagocytosis (Shaw et 
al.. 2000) and after binding of LAM (Dahl et al., 1996), by dendritic cells and 
macrophages (Tufariello et al., 2003). IL-10 downregulates the production of pro-
inflammatory cytokines IFN-y, TNF-a and IL-12 (Fulton et al., 1998; Hirsch et al., 
1999). IL-10 can deactivate macrophages and dampen the immune response to 
prevent or limit pathology from an over-exuberant inflammatory response to a 
pathogen. This cytokine may have a role in the chronic phase of infection, since 
downregulation of a type I immune response is likely to be beneficial to the host, 
at least in terms of lung pathology (Tufariello et al., 2003). IL-10 expression in 
tuberculosis has been demonstrated in circulating mononuclear cells, at the site 
of disease in pleural fluid and in alveolar lavage fluid (Barnes et al., 1993; Gerosa 
etal., 1999). 
(ii) TGF-p: 
TGF-p is produced by monocytes and dendritic cells following induction by 
mycobacterial products (Toossi et al., 1995). TGF-p suppresses cell-mediated 
immunity; in T cells it inhibits proliferation and IFN-y production; in macrophages 
it antagonizes antigen presentation, pro-inflammatory cytokine production, and 
cellular activation. TGF-p may be involved in tissue damage and fibrosis during 
tuberculosis, as it promotes the production and deposition of macrophage 
collagenases (Toossi and Ellner, 1998). 
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(iii) IL-4: 
IL-4 has deleterious effects in tuberculosis, which have been ascribed to this 
cytokine's suppression of IFN-y production (Powrie and Coffman, 1993) and 
macrophage activation (Appelberg et al., 1992). 
NF-KB activation - Role in innate immunity: 
It is well established that the classical NF-KB pathway, based on IKKp-dependent 
IKB degradation, is essential for innate immunity (Bonizzi and Karin, 2004). The 
activation and nuclear translocation of classical NF-KB dimers is associated with 
increased transcription of genes encoding chemokines, cytokines, adhesion 
molecules [intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and endothelial-leukocyte adhesion molecule-1 (ELAM-1)], 
enzymes that produce secondary inflammatory mediators and inhibitors of 
apoptosis (Ghosh et al., 1998). These molecules are important components of 
the innate immune response to invading microorganisms and are required for 
migration of inflammatory and phagocytic cells to tissues where NF-KB has been 
activated in response to infection or injury (Bonizzi and Karin, 2004). Indirect 
pathways that lead to NF-KB activation are illustrated by infection of pulmonary 
epithelial cells with M. tuberculosis, which results in the release of IL-1 and 
activation of the classical NF-KB pathway in adjacent cells (Wickremasinghe et 
a!., 1999). 
Tumor necrosis factor-alpha (TNF-a): 
TNF-a was first discovered in 1975 as a macrophage-derived molecule that 
induced a haemorrhagic necrosis of tumors transplanted subcutaneously in mice 
(Carswell et al., 1975). It is a member of the TNF superfamily of cytokines, 
consisting mainly of homotrimeric proteins involved with immune regulation and 
inflammation that includes lymphotoxin-a (TNF-P), CD40 ligand and Fas ligand 
(Darnay and Agganwal, 1999). TNF-a is a pleiotropic cytokine that plays a central 
role in inflammation and apoptosis (Sedgwick et al., 2000; MacEwan, 2002). It is 
synthesized as a 26 kDa, type H transmembrane protein that is 233 amino acids 
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in length (Pennica et al., 1984; MacEwan, 2002). It contains a 30 amino acids 
cytoplasmic domain, a 26 amino acids transmembrane segment, and a 177 
amino acids extracellular region (Wang et al., 1985; Ishisaka et al., 1999). TNF-a 
is assembled intracellularly to form a transmembrane, non-covalently-linked 
homotrimeric protein. The 157 amino acids residue soluble form of TNF-a (sTNF-
a) is released from the C-terminus of the transmembrane protein through the 
activity of TNF-a-converting enzyme (TACE), a membrane-bound disintegrin 
metalloproteinase (Moss et al., 1997; Kriegler et al., 1988). 
The granulomatous immune response is characterized by delayed hypersensitivity 
and is mediated by various cytokines released by the stimulated mononuclear 
phagocytes, including TNF-a (Morimoto et ?!., 1989; Ellner and Wallis, 1989). 
TNF-a is a pro-inflammatory cytokine and following appropriate stimulation, many 
cells produce TNF-a. The main cellular sources of TNF-a during an inflammatory 
response are monocytes (Frankenberger et al., 1996) and macrophages (Sakurai 
et al., 1985), but it can also be produced by other cells including NK cells, T and 
B lymphocytes (Ware et al., 1992), mast cells (Bissonnette et al., 1995), dendritic 
cells (Zhou and Tedder, 1995), astrocytes (Lee et al., 1993), osteoblasts 
(Modrowski et al., 1995) and neurons (Tchelingerian et al., 1996). Expression of 
the TNF-a gene in macrophages can be stimulated by both exogenous and 
endogenous factors: bacteria, viruses, parasitic organisms, irradiation, trauma, 
ischemia, cytokines [IL-ip, IL-2, IFN-y, granulocyte macrophage colony-
stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF)] 
and by TNF-a itself (Larche et al., 2005). Lipopolysaccharide (LPS) and bacterial 
products are strong stimuli of TNF-a synthesis (Bazzoni and Beutler, 1996). TNF-
a is recognized as a significant mediator of macrophage activation for 
intracellular killing of bacilli following ingestion by phagocytic cells (Wallis et al., 
1993). Evidence is accumulating that TNF-a is vital to host defense and 
antibacterial resistance against infections caused by facultative intracellular 
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organisms, particularly by M. tuberculosis which is a potent inducer of cytokine 
production (Valone et al., 1988; Takashima et al., 1990). 
Although this cytokine is involved in multiple cell regulatory and differentiation 
processes leading to immunity in tuberculous infection, however, TNF-a also 
mediates effects deleterious to the host contributing to the pathophysiology of 
tuberculosis. High levels of the cytokine at the site of infection induce an 
excessive damaging inflammatory response tnat overwhelms its beneficial 
effects (Bekker et al., 2000). Therefore, an understanding of the mechanisms 
that regulate TNF-a expression is important in achieving a harmonious balance 
between the outcome of both its beneficial and pathologic effects. 
(A) Ligand structure and receptors: 
The crystal structure of TNF indicates that it is biologically active as a trimer, both 
as a soluble and as a transmembrane factor (McWhirter et al., 1999; Idriss and 
Naismith, 2000). The type II transmembrane protein TNF can be considered as 
the prototype of the TNF cytokine superfamily, a core group of structurally related 
ligands [encompassing lymphotoxin (LT)a, LTP, and LIGHT] (Locksley et al., 
2001; Granger and Ware, 2001). The TNF cytokine family members interact with 
more than one receptor of the corresponding superfamily of cognate receptors. 
These cytokines and receptors play important roles in the coordinated 
development of the immune system and the protection from pathogens (Pfeffer, 
2003). 
Both the homotrimer TNF receptors, TNFR-I (TNFRp55: 55 kDa) and TNFR-II 
(TNFRp75: 75 kDa) interact with, and are involved in binding and signal 
transduction to both soluble and transmembrane TNF (Ehlers, 2003). However, 
the membrane-associated form mostly binds to TNFR-II, whereas soluble TNF 
preferentially binds to TNFR-I, with greater functional consequences than the 
former (Papadakis and Targan, 2000). TNFR-I contains a characteristic structural 
cassette, termed death domain, in its intracytoplasmic sequence that is 
conserved within a distinct subset of other TNFR family members, such as CD95, 
DR3, DR4 and DR5 (Tartaglia et al., 1993; Locksley et al., 2001). 
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(B) TNF-a signal transduction machinery: 
TNFR-I has been shown to be essential for surviving infections with 
intracellular bacteria, such as M. tuberculosis, Salmonella typhimurium, M. 
avium, Listeria monocytogenes (Pfeffer et al., 1993; Everest et al., 1998; Ehlers 
et al., 1999). The death domain is required for the signal transduction of the 
functions of TNFR-I in vivo (Plitz et al., 1999). TNF-a exerts its functions by 
interaction with the death domain-containing TNFR-I and the non-death domain-
containing TNFR-II. Important proteins that interact directly or indirectly with the 
cytoplasmic domains of TNFR-I and TNF."^ -II are receptor-interacting protein 
(RIP), a serine/threonine kinase, and TNF receptor-associated factor (TRAF)-I 
and -2 (Orlinick and Chao, 1998; Verrecchia and Mauviel, 2004). RIP is required 
for NF-KB activation in response to TNF-a but not IL-1 or LPS (Kelliher et al., 
1998). TRAF-1 and -2 define a novel group of adaptor proteins involved in signal 
transduction by most members of the TNF receptor family, of IL-1 receptor and 
IL-17 receptor, as well as some members of the TLRs family (Verrecchia and 
Mauviel, 2004). TRAF-2 is currently the best-characterized TRAF family member, 
having a key role in mediating TNFR1-induced signalling cascades leading to 
activation of NF-KB and JNK (c-Jun N-terminal kinase) (Wajant and Scheurich, 
2001; Chen and Goeddel, 2002). 
(1) NF-KB activation pathway: 
NF-KB proteins are a family of cytoplasmic heterodimeric transcription factors 
that are inactive due to their association with an inhibitory protein IKB (Verrecchia 
and Mauviel, 2004). Potent activators, such as TNF-a, IL-1, or LPS, activate IKK 
complex (Bonizzi and Karin, 2004). Once activated, IKK induces rapid 
degradation of the IKBS (especially IKBO) within minutes. For IKBO this 
degradation process consists of a series of well-characterized steps, which seem 
to be relevant to the other IKBS (Baldwin, 1996; Ghosh e* al., 1998). Inducible IKB 
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phosphorylation, one of the earliest events in the common activation pathway, 
occurs at serines 32 and 36 in kBa, and mutation of either serine (even to a 
threonine) greatly inhibits the degradation process (Traenckner et al., 1995, 
DiDonato et al., 1996). Phosphorylation lesds to the immediate recognition of 
IKBQ by the recently identified F-box/WD40 E3RS'''^/p-TrCP (Yaron et al., 1998; 
Laney and Hochstrasser, 1999; Maniatis, 1999), which consequently results in 
the polyubiquitinylation of IKBQ primarily at lysines 21 and 22 by an SKpl-Cullin-
F-box (SCF)-type E3 (Scherer et al., 1995; Baldi et al., 1996). This modification 
then targets IKBQ for rapid degradation by the 26S proteasome. 
The degradation of its inhibitor exposes the nuclear localization sequence (NLS) 
of NF-KB resulting in binding to karyopherins and translocation of NF-KB to the 
nucleus (Karin and Ben-Neriah, 2000). It is important that inhibitors of the 26S 
proteasome efficiently block NF-KB nuclear translocation, indicating that neither 
phosphorylation nor ubiquitinylation is sufficient to dissociate IKB from NF-KB 
(DiDonato et al., 1995; Alkalay et al., 1995). 
TNF-a blockade: Anti-TNF-a agents: 
Attenuation of the biological activity of TNF has lately become an important 
therapeutic intervention in the management of a wide variety of chronic 
inflammatory diseases (Shanahan and St Clair, 2002). Currently two major 
protocols are being used for the treatment of various chronic inflammatory 
diseases: Infliximab, an anti-TNF-a neutralizing antibody, and Etanercept, a 
recombinant molecule made up of two Identical chains of the human 75 kDa TNF 
receptor II fused to the Fc portion of human IgGI (Gardam et al., 2003). 
Infliximab is a human-murine (25% murine) chimeric monoclonal antibody with 
high binding affinity (Bekker et al., 2000) and specificity for TNF-c (Knight et al., 
1993). It forms stable complexes with the monomeric and trimeric forms of 
soluble TNF-a and with the transmembrane forms of TNF-a (Scallon et al., 
2002^ !{ also has the ability to cross-link TNF-a molecules. Binding to 
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transmembrane TNF-a results in macrophage and monocyte lysis by cytotoxicity 
that depends on antibodies and complement (Lugering et al., 2001). Infliximab 
does not bind to related cytokines, such as TNF-P, which is involved in the Th1 
response (Falcone et al., 1994). 
There are subtle differences in the mechanisms of action of these two agents; in 
particular, drug-mediated apoptosis and monocytopenia appear to be unique to 
infliximab (Gardam et al., 2003). Infliximab binds more avidly than etanercepi 
does to transmembrane TNF-a and form a more stable complex. Infliximab is 
more effective at inhibiting transmembrane TNF-a-mediated activation of 
endothelial cells. Infliximab binds both the monomeric and trimeric form of 
soluble TNF-a, whereas etanercept effectively binds only to the trimeric form. 
Etanercept-TNF-a complexes are unstable, resulting in the release of soluble 
TNF-a. On the basis of these differences, infliximab might be predicted to have a 
more significant effect on the host's ability to suppress M. tuberculosis infection 
(Gardam et al., 2003). 
CORRELATION BETWEEN TUBERCULOSIS AND AUTOIMMUNE 
DISEASES: 
Like HIV-tuberculosis, SLE -TB association commonly exists as shown by 
various studies. The association of SLE with tuberculosis (TB) was studied in a 
group of 388 patients with SLE monitored between 1953-1994. TB was 
diagnosed in 14 patients (3.6%). The occurrence of septic fevers in SLE patients 
that did not respond to glucocorticoid therapy indicated the possibility of 
complication with TB (Rovensky et al., 1996). In a retrospective analysis of 146 
systemic lupus erythbematosus (SLE) patients seen over a 5 year period, 17 
patients of tuberculosis (TB) were laentified yielding a prevalence rate of 11.6% 
(Balakrishnan et al., 1998). Results of the 526 SLE patients, 57 (11%) had TB. 
There is a high prevalence of TB, especially extra-pulmonary diseases, among 
SLE patients. High cumulative dose of corticostp'-oid and lupus nephritis are 
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important risk factors for the development of TB (Tam et al., 2002). Of the 556 
patients evaluated, 20 patients (3.6%) with TB were identified. An increased 
frequency of TB infection and a high prevalence of extrapulmonary TB v^ /ere 
observed in a large cohort of SLE patients. The mean daily dose of prednisolone 
before the diagnosis of TB and the cumulative dose of prednisolone, which 
possibly related to disease severity, were important determinants for the 
increased risk of TB in these patients with SLE (Sayarlioglu et al., 2004). These 
results might help to interpret the magnitude of the problem attributable to the 
introduction of new therapies in RA (Carmona L, et al., 2003). Tuberculosis was 
documented in 15 SLE and 7 RA patients with an incidence rate of 7.9/1,000 
patient-years and 2.3/1,000 patient-years, respectively (p=0.003). 
Conclusion: Taken together, the characteristics of tuberculosis in autoimmune 
disorders patients were: 
(1) higher incidence rate with SLE patients, 
(2) more frequent extra-pulmonary involvement, 
(3) more extensive pulmonary involvement, and 
(4) higher relapse rate than in rheumatoid arthritis. 
Thus, the contributory role of M. tuberculosis infection in the morbidity and 
mortality of patients with SLE must be emphasized, especially in areas in which 
this bacterium is endemic (Yun et al., 2002). In long-term corticosteroid, 21 of 
these patients developed active tuberculosis. The incidence of active 
tuberculosis is increased in rheumatic patients on moderate-to-high dose steroid 
treatment (Kim et al., 1998). 
INFLAMMATORY MARKERS IN AUTO IMMUNE DISORDERS 
Cytokines are soluble proteins produced by a wide variety of hematopoietic and 
nonhematopoietic cell types. They are critical for both normal innate and adaptive 
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immune responses, and their expression may be perturbed in most immune, 
inflammatory, and infectious disease states. 
Cytokines are involved in tl.e regulation of the growth, development, and 
activation of immune system cells and in the mediation of the inflammatory 
response. In general, cytokines are characterized by considerable redundancy in 
that different cytokines have similar functions. In addition, many cytokines are 
pleiotropic in that they are capable of acting on many different cell types. This 
pleiotropism results from the expression on multiple cell types of receptors for the 
same cytokine, leading to the formation of "cytokine networks". The action of 
cytokines may be: 
(1) autocrine when the target cell is the same cell that secretes the 
cytokine, 
(2) paracrine when the target cell is nearby, and 
(3) endocrine when the cytokine is secreted into the circulation and acts 
distai to the source. 
THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR FAMILIES 
Tumor necrosis factor (TNF-a) and lymphotoxin-a were isolated more than 10 
years ago, on the basis of their ability to kill tumor cells in vitro and to cause 
hemorrhagic necrosis of transplantable tumors in mice (Carswell et al., 1975). 
The complementary DMAs and genes encoding each protein were cloned 
immediatefy thereafter (Pennica ef a(., 1984; Aggarwaf et al., 1984). 
Concurrently, a factor known as cachectin was isolated from mouse 
macrophages, sequenced, and shown to be identical to TNF-a (Beutler et al., 
1985). Cachectin was identified not as a cytolysin, but as a catabolic hormone 
that suppressed the expression of lipoprotein lipase and other anabolic enzymes 
(Kawakami et al., 1982; Pekala et al., 1984; Torti et al., 1985). Still other studies 
demonstrated the powerful pro-inflammatory effects of TNF-a (Dayer et al., 1985; 
Gamble et al., 1985) and revealed its role as a central endogenous mediator of 
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endotoxic shock (Beutler et al., 1985; Tracey et al., 1986). Hence, TNF-a has a 
broad spectrum of biologic activities. 
Because it proved to be highly toxic in animals and humans, TNF-a did not fulfill 
initial expectations that it would be useful in the treatment of cancer. However, 
considerable evidence suggests that overproduction or inappropriate production 
of TNF-a may play a part in various chronic inflammatory diseases. Produced 
largely by macrophages in response to inflammatory stimuli such as 
lipopolysaccharide, TNF-a binds to receptors present on virtually all cells 
throughout the body. TNF-a, if released systemically in large amounts all at once, 
modifies the anticoagulant properties of endothelial cells, activates neutrophils, 
and induces the release of other inflammatory cytokines. These effects culminate 
in cardiovascular collapse. By contrast, chronic, low-level production of TNF-a 
may contribute to the inflammatory response. Bone resorption, fever, anemia, 
and wasting may all, in some measure, be attributable to TNF-a (Beutler et al., 
1992). TNF-a is one of 10 known members of a family of ligands that activate a 
corresponding family of structurally related receptors. 
The receptors initiate signals for cell proliferation and apoptosis (programmed cell 
death). These signals are required for the normal development and function of 
the immune system. Excessive signaling through some of the receptors can 
cause severe inflammatory reactions, tissue injury, and shock. Mutations of the 
genes corresponding to the ligands or the receptors can cause characteristic 
disturbances of lymphocytes, derangement of the immune response, or 
autoimmune disease. 
All members of the TNF- ligand family are believed to consist of three polypeptide 
chains. All but lymphotoxin-p (which consists of a single lymphotoxin-a subunit 
and two lymphotoxin-p subunits) are made up of three identical subunits. All 
except lymphotoxin-a (which is entirely secreted) and TNF-a (which is 
predominantly secreted) are transmembrane proteins that act chiefly through cell-
to-cell contact. Nerve growth factor, a dimeric protein, is not actually a member of 
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the TNF-ligand family. Rather, it was apparently adapted in the course of 
evolution to serve its receptor, a true member of the TNF-a receptor family. 
All members of the TNF-a receptor family are believed to be transmembrane 
proteins that consist of two identical subunits. The family is defined by a cysteine-
rich amino-acid motif that recurs three to six times in the extracellular domain. 
The cytoplasmic domains vary more than the extracellular domains. Notably, 
certain receptors contain a 60-residue cytoplasmic sequence known as the 
"death domain." In the 55-kd TNF-a receptor and the Fas receptor, this domain is 
required for the transduction of an apoptotic signal. 
With the exceptions of TNF-a and lymphotoxin-a each member of the ligand 
family binds to a specific receptor. TNF-a and lymphotoxin-a engage two 
receptors (the 55-kd and 75-kd TNF-a receptors) with similar affinity. These two 
cytokines initiate similar (if not identical) biologic responses, although they are 
produced by different types of cells (lymphotoxin-a is produced exclusively by 
lymphocytes and natural killer cells, and TNF-a predominantly by macrophages) 
in response to different stimuli (antigenic or mitogenic stimuli for lymphotoxin-a 
and lipopolysaccharide or other macrophage-activating agents for TNF-a). 
Functions of TNF- Ligands and Receptors 
For many years, the role of members of the TNF- ligand and TNF-a receptor 
families in immunity and in the development of the immune system remained 
speculative. The first indication of their function came from the finding that 
mutations of the ligands or their receptors could cause disease. Striking 
examples are the Ipr (lymphoproliferation) and gid (generalized 
lymphoproliferative disease) mutations of mice, which were found to specify 
defects of the Fas receptor (Ipr) and the Fas ligand {gId). These mutant mice 
have long been taken as models of systemic lupus erythematosus because they 
have lymphadenopathy and splenomegaly and form autoantibodies (Izui et al., 
1984; Roths et al., 1984). In the homozygous state, each mutation causes the 
accumulation of large numbers of T cells lacking the CD4 and CD8 surface 
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proteins. Heterozygous pairing of the /p/^° allele (CG denotes "complements glcf') 
with the gid allele also causes lymphoproliferation, suggesting that the products 
of the two loci might interactwith one another (Matsuzawa et al., 1990). 
Further study demonstrated that the /p r ° allele encodes a mutant Fas receptor 
that can bind its ligand but lacks signal-transducing activity. The classic Ipr 
mutation, by contrast, abolishes the expression of the Fas receptor (Allen et al., 
1990; Watanabe-Fukunaga et al., 1992; Adachi et al., 1993). The /p/^° allele 
contains a point mutation within the death domain of the Fas receptor that 
prevents signal transduction but does not affect ligand binding (Watanabe-
Fukunaga et al., 1992). The gId allele contains a point mutation that inactivates 
the Fas ligand (Suda et al., 1993). It is widely suspected that mutations of the Fas 
ligand or its receptor cause a failure of apoptosis in T lymphocytes. This, in turn, 
leads to massive accumulations of lymphocytes in lymph nodes and spleen and 
features of autoimmunity. 
Other members of the TNF- ligand and TNF-a receptor families are also 
important in immune function. For example, the syndrome of X-linked 
immunodeficiency, in which there are high levels of IgM and low or absent levels 
of other immunoglobulins, is caused by a mutation in the CD40 ligand (Allen et 
al., 1993; Korthauer et al., 1993). Interaction of the CD40 ligand on T cells with 
the CD40 receptor on B cells mediates immunoglobulin-class switching (the 
conversion from the production of IgM antibodies to the production of IgG 
antibodies) and clonal expansion of antigen-responsive B cells. In mice, deletion 
of the CD40-ligand or CD40-receptor genes results in a phenotype that 
resembles the disease that occurs in humans (Xu et al., 1994; Kawabe et al., 
1994). 
How the Receptors Work 
Interactions between TNF-a and its receptors are presumably typical of 
interactions between the other ligand-receptor pairs in these two molecular 
f?"^:!ies. Trimeric ligands of the TNF-a family may cause aggregation or 
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clustering of receptor subunits, thereby triggering a cellular response, since 
antibodies against either of the two TNF-a receptors mimic the actions of TNF-a 
(Engelmann et al., 199C; Tartaglia et al., 1993). Support for the aggregation 
model is bolstered by the crystal structure of lymphotoxin-a, which forms a 
complex with extraceiiular-domain fragments of the 55-kd TNF receptor, (Banner 
et al., 1993) in which three receptor fragments crystallize with each lymphotoxin-
atrimer. 
One of the most intriguing actions of TNF-a is the induction of apoptosis. 
Apoptosis is almost certainly relevant to some of the toxic effects of TNF-a, such 
as shock and inflammation. TNF-a induced apoptosis may also have physiologic 
relevance, as does the apoptosis induced by the Fas receptor. It is possible, for 
example, that TNF-a mediated apoptosis of infected cells helps protect the host. 
It is likely that both TNF-a receptors participate in cell death, although the 55-kd 
receptor is more potent than the 75-kd receptor. Since the cytoplasmic domains 
of the two receptors are structurally different, each must initiate apoptosis through 
distinct mechanisms. 
An entirely different class of cytoplasmic proteins binds to the 55-kd TNF-a 
receptor and the Fas receptor. These proteins are important in transducing 
signals for programmed cell death. The Fas-associated death domain (FADD), 
(Chinnaiyan et al., 1995) also called MORT-1, (Boldin et al., 1995) the TNF-a 
receptor-associated death domain (TRADD), (Hsu et al., 1995) and the receptor 
interacting protein (RIP) (Stanger et al., 1995) bind to the Fas receptor, the 55-kd 
TNF-a receptor, and both receptors, respectively. Each of these proteins 
contains a version of the death domain found within the receptors themselves. 
This motif permits interaction between receptor and transducer molecules. 
FADD (Boldin et al., 1995; Chinnaiyan et al., 1995) is a proximal transducer of 
the apoptotic activity of the Fas receptor, with which it forms a heterodimer. 
Engagement of the ligand causes the release of homodimeric FADD, which 
relays the death signal to the cytoplasm. FADD is incapable of forming 
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heterodimers with receptors encoded by the mutant Ipr^'^ gene. Hence, it is at 
precisely this level that the /p/^° mutation interrupts signaling. 
Acting in an analogous fashion, TRADD is a proximal transducer of apoptosis 
mediated through the 55-kd TNF-a receptor (Hsu et al., 1995). RIP appears to 
serve both the 55-kd TNF-a receptor and the Fas receptor. The transducers may 
interact with distinct targets downstream from the receptor. Although 
overexpression of any of the transducers can initiate cell death, different portions 
of each protein act to carry the apoptotic signal fonward within the cytoplasm 
(Cleveland et al., 1995). Moreover, RIP is far larger than either TRADD or FADD 
and contains a kinase domain (Cleveland et al., 1995). 
In accordance with the molecular-switch hypothesis, a receptor modified by the 
binding of ligand might effectively catalyze the formation of homodimeric FADD, 
TRADD, or RIP. Causing conformational changes in these molecules that lead to 
further reactions in the signaling cascade. This scenario is consistent with the 
observation that modified receptors are constitutively activated in the absence of 
ligand (Bazzoni et al., 1995). 
CORRELATION OF TNF-a AND AUTOIMMUNE DISEASES 
Low levels of TNF-a may account for the state of insulin resistance that 
contributes to the development of type-1 diabetes mellitus (Hotamisligil et al., 
1995; Hofmann et al., 1994; Hotamisligil et al., 1994; Hotamisligil et al., 1993; 
Spiegelman et al., 1993). The lupus-like state that follows abrogation of the 
function of the Fas ligand or receptor suggests that some autoimmune disorders 
could involve defects in the Fas- or TNF-a signaling axes. The observation that 
the administration of TNF-a attenuates or prevents some autoimmune diseases 
in animals supports this view. (Jacob et al., 1990; Yang et al., 1994; Yang et al., 
1998). Both TNF-a and interleukin-1 are likely to have primary roles in the 
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pathogenesis of rheumatoid arthritis. The serum and synovial concentrations of 
both cytokines are high in patients with active rheumatoid arthritis. 
CORRELATION OF TNF-a AND TUBERCULOSIS 
Initiation of TNF-a clearly predisposes to certain infections, such as 
granulomatous infection like Tuberculosis (Islam et al., 2004; Wilkinson et al., 
2001). A definite correlation exists between nitric oxide release and TNF-alpha 
production, irrespective of low or high production in MDR-TB or fresh cases, 
respectively. The present data suggest that peripheral blood monocytes of MDR-
TB patients typically show signs of immunosuppression. Whether such 
immunodepression is the cause or the effect of MDR-TB merits further 
investigation (Sharma et al., 2004). Data suggest that the PBMC of MDR-TB 
patients typically show TNF-alpha depression in response to the 30-kDa 
antigens, and this effect is modulated by IL-10. In addition, we highlight the role 
of TNF-alpha in IL-8 secretion in MDR-TB patients. (Lee et al., 2003). Findings 
may indicate that, during TB, predisposition of CD4 T-cells to apoptosis may 
involve both low expression of Bcl-2, and excessive expression of TGF-beta, 
TNF-alpha and Fas-L. (Hirsch et al., 2005). The serum TNF-a, soluble CDS 
(sCD8) and soluble interleukin-2 receptor (SIL-2R) levels were probed in children 
with active pulmonary tuberculosis (n=66) and healthy controls (n=20). 
Measurable serum TNF-a levels were detected in nine of 86 children (10.5%), all 
of who belonged to the group with active disease. Serum sCD8 and SIL-2R 
detemninations revealed a significant difference between the group with active 
puln)onary tuberculosis and the controls (p<0.05) (Barlan et al., 1995). Findings 
suggest that the underlying mechanisms of cytokine regulation might differ 
between N-TB and R-TB patients, and that decreased IL-12 production in 
response to the 30-kDa or PPD Ag might be involved in the immunopathogenesis 
of human R-TB. (Lee et al., 2002). The increases of TNF-alpha and IL-12 level 
were observed in comparison to control group. TNF-alpha concentration was 
about 2-fold higher in the positive patients than it was in control group; IL-12 
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concentration was about 4-foid higher and the differences between IL-12 levels 
were statistically important (p<0.05). However, no significant differences were 
found in IFN-gamma level among all groups. Using Spearman correlation rank 
test, a significant correlation was found between TNF-alpha and IL-12 in the 
positive patient group. The correlation factor was more significant for the group of 
patients with Mycobacterium tuberculosis present in blood and urine than it was 
in urine positive PCR group (r= -0.66 vs. r= -0.51) (Koziol-Montewka et al., 2004). 
OXIDATIVELY MODIFIED AUTOANTIGENS IN AUTOIMMUNE DISEASES 
Reports indicate (Kurien et al., 2006) that free radical-mediated oxidative 
damage and consequent protein modification by the end products of oxidative 
damage are important mediators of cell toxicity and disease pathogenesis. 
Aldehydic products, mainly the 4-hydroxy-2-alkenals, form adducts with proteins 
and make them highly immunogenic. Oxidative modification of proteins has been 
shown to elicit antibodies in a variety of diseases including systemic lupus 
erythematosus (SLE), alcoholic liver disease, diabetes mollitus (DM), and 
rheumatoid arthritis (RA). Oxidatively modified DNA (8-oxodeoxyguanine) and 
low-density lipoproteins (LDL) occur in SLE, a disease in which premature 
atherosclerosis is a serious problem. In addition, it has been reported that 
immunization with 4-hydroxy-2-nonenal (HNE)-modified 60-kDa Ro autoantigen 
elicits an accelerated epitope spreading in an animal model of SLE. Advanced 
glycation end product (AGE) pentosidine and AGE-modified IgG have been 
shown to correlate with RA disease activity. Oxidatively modified glutamic acid 
decarboxylase is important in type 1 DM, while autoantibodies against oxidized 
LDL are prevalent in Behcet's disease. The fragmentation of scleroderma-
specific autoantigens occurs as a result of oxidative modification and is thought 
to be responsible for the production of autoantibodies through the release of 
cryptic epitopes. In the face of overwhelming evidence for the involvement of 
oxidative damage in autoimmunity the administration of antioxidants is a viable 
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untried alternative for preventing or ameliorating autoimmune disease, although 
results in cardiovascular disease were disappointing (Kurien et al., 2006). 
Furthermore, free radical mediated peroxidative damage resulting in augmented 
MDA levels in systemic lupus erythematosus patients has been well established 
(Kurien and Scofield, 2003) 
Natural antioxidant In disease prevention - EGCG (Epigallocatechin-3-
gallate) from Green Tea: 
Tea {Camellia sinensis) has been used as a daily beverage for several 
thousand years since it was introduced as a beverage in China that is now the 
second most common beverage consumed by humans (Weisburger, 1999). 
Even though it has been known traditionally that tea may have some beneficial 
health effects, such effects were not demonstrated by well-controlled 
laboratory studies until the 1970s (Weisburger, 1999). However, recent studies 
have revealed the biological effects of tea, such as antitumor as well as 
antimicrobial effects, even at the molecular level. The active components of 
tea responsible for such biological effects are now known to be catechins (also 
known as polyphenols), which constitute seven forms, including 
epigallocatechin gallate (EGCG). EGCG is a major catechin compound in tea 
extracts and is also the most active form among the tea catechins in a variety 
of biological activities. For instance, EGCG has anticarciogenic (Katiyar et al., 
1993; Yamane. et al., 1995), antioxidant (Ho et al., 1992), as well as 
antimicrobial activities (Yam et al., 1997; Yam et al., 1998). Although the 
mechanism of antimicrobial activity of EGCG has been studied, it is still 
unclear till date. However, the immunomodulatory effect of EGCG has been 
increasingly recognized, since the bioavailability of EGCG in plasma after 
drinking tea is known to be high (Yang et ai., 1996). in fact, it is known that 
EGCG potently stimulates the production of interleukin-1 alpha (IL-la), IL-1b, 
and tumor necrosis factor alpha (TNF-a) by cultured human peripheral blood 
mononuclear cells (Katiyar, S. et al., 1999). Furthermore. EGCG protects 
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against UV radiation-induced immunosuppression and tolerance induction by 
reducing IL-10 production and increasing IL-12 production in epidermal and 
dermal cells (Sakagami et al., 1995). However, the detailed 
immunomodulatory effects of EGCG on immune cells have not been 
investigated. The chemical structure of EGCG is given below. 
H0x.^.-=^. .^0v2 
Hydroxyl groups 
Catechol group 
y Gallate group 
Objectives of the present study: 
Thus, in the present study, investigations were carried out on an appreciable 
number of SLE autoimmune disorder patients for immunological evaluation of 
Mycobacterium tuberculosis infection admitted or attending Medical OPD's of J. 
N. Medical College Hospital. The study was carried out to achieve the following 
objectives: (a) to probe the incidence for clinical characteristics of Mycobacterium 
tuberculosis infection in patients with SLE autoimmune disorder, (b) to evaluate 
the effect of Mycobacterium tuberculosis infection on the clinical course of 
morbidity, mortality of autoimmune disorders and vice-versa and (c) to correlate 
various immuno-inflammatory markers with disease activity in Tuberculosis 
associated autoimmune diseases. Briefly, in this investigation, a systematic study 
was carried out using the techniques of real-time RT-PCR, direct binding ELISA 
and competition ELISA to characterize the sera and monocytes of patients with 
SLE, TB and SLE-TB with respect to TNF-a. The modulatory effects of the 
natural antioxidant EGCG and NAC on monocyte cultures of SLE, TB and SLE-
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TB patients were evaluated at the protein level as well as immunologically. To 
fully delineate the contribution of the innate immune response to the 
pathogenesis of the above diseased patients, liie roies played by ROIs and 
RNIs, induction of TNF-a, activation of NF-KB and monocyte activation were 
examined and correlated by immunological investigations. 
Toxicity assessment of EGCG on viability of human monocytes was assessed by 
cell viability assays like MTT and trypan blue exclusion assay as well as by 
assessing human housekeeping genes like 18S rRNA by real-time RT-PCR, 
respectively. RT-PCR, real-time RT-PCR and ELISA probed the effects of allicin 
on expression of TNF-a and M. tuberculosis 85B in M. tuberculosis-infected 
monocytes after 24 hours of infection. Commercially available ELISA kits 
assessed the repertoire of TNF-a in supernatants of monocyte cultures from 
patients and healthy controls that were treated and untreated with EGCG. 
Glutathione peroxidase activities as well as MDA levels due to lipid peroxidation 
were evaluated in patient's monocytes in the presence or absence of EGCG, and 
in turn, were correlated with binding studies in immunological investigations. 
It is hoped that the data generated in the present study may help in the better 
understanding about the etiology and trigger / autoantigen contributing towards 
SLE. 
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MATERIALS AND METHODS: 
Materials 
Monoclonal anti-TNF-a antibody, N-acetyl-cysteine (NAC), SN50 (an inhibitor of 
NF-KB) and its analogue SN50/M, Epigallo-catachin-3-gallaterum, Bovine Serum 
Albumin, Coomassie Brilliant Blue G-250 and R-250, p-nitrophenyl phosphate, 
anti-human IgG alkaline phosphate conjugate, Tween-20, dithiothreiotol, 
phenylmethylsulphonyl fluoride, standard protein markers, protein A sepharose 
CL-4B, sodium azide, ethidium bromide, chloroform, isoamyl alcohol, reduced 
glutathione, glutathione reductase, cumene hydroperoxide and reduced P-
nicotinamide adenine dinucleotide phosphate were from Sigma Chemical 
Company, U.S.A. SN50 is a hybrid peptide containing nuclear localization 
sequence of p50 subunit of NF-KB heterodlmer and has been shown to 
completely inhibit the translocation of NF-KB in human cell lines at 100 |jg/ml (Lin 
etal., 1995). 
Ficoll-Paque was from Pharmacia, Piscataway, NJ, U.S.A. Middlebrook 7H9 
broth, Middlebrook ADC enrichment fluid, RPMI-1640 medium were from 
HiMedia, India. MTT cell viability assay kit and immunoassay kits for TNF-a were 
of R & D Systems, U.S.A. 12-wells tissue culture plates were obtained from 
Techno Plastic Products (TPP), Switzerland. Polystyrene microtitre flat bottom 
ELISA plates having 96 wells (7 mm diameter) were from NUNC, Denmark. A 
colorigenic substrate p-nitrophenyl phosphate was obtained from C.S.I.R. Centre 
for Biochemicals, New Delhi. Asparagine, citric acid, magnesium sulphate, 
dipotassium hydrogen phosphate, ferric ammonium citrate and glycerol were 
obtained from Qualigens, India. Sodium pyruvate was obtained from SRL, India. 
All other chemicals were of highest grade available. 
Study subjects: 
For isolation of peripheral blood mononuclear cells (PBMC's) or serum, venous 
blood was obtained from patients with systemic lupus erythematosus (SLE), 
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tuberculosis (TB) and SLE-TB admitted or attending O.P.D. at J.N. Medical 
College Hospital of A.M.U, Aligarh. Also, for some experiments involving in vitro 
infection with pathogenic strain of MTB for using the infected cells as valuable 
antigens / inhibitors in immunoassays, we obtained healthy nonsmoking adult 
volunteers with no history of tuberculosis or positive tuberculin skin test. The SLE 
sera showed high titer anti-DNA antibodies and fulfilled the American College of 
Rheumatology (formerly American Rheumatism Association) revised criteria for 
the classification of SLE (Arnett et al., 1988). Serum samples were 
decomplemented by heating at 56°C for thirty minutes and stored in small 
aliquots at -20°C until use with 0.1 percent sodium azide as preservative. 
Exclusion criteria 
Patients who have already received steroids/cyclophosphamide and other 
immunosuppressant as well as patients having hepatitis, septicemia, multi organ 
failure, were excluded from the study. 
Methods 
Determination of protein concentration: 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford (1976) 
(data not shown). 
(A) Protein estimation by the Lowry (Folin-Ciocalteau) method: 
Protein estimation by this method involves complexing of the protein's peptide 
bonds with Cu^* under alkaline conditions (Lowry et al., 1951). The resultant Cu* 
appears to catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Folin reagent (a mixture of sodium 
tungstate, molybdate and phosphate), added subsequently. This reaction 
develops a blue colour due to the formation of heteropolymoiybdenum blue, 
which can be quantified by its absorbance at 660 nm. 
Reagents: 
(i) Folin-Ciocaiteau reagent 
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The reagent was diluted 1:4 with distilled water before use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two 
components in the ratio 50:1, respectively. 
Procedure: 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline copper 
reagent. After thorough mixing, the reaction mixture was allowed to stand at 
room temjaerature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times 
diluted Folin-Ciocalteau reagent. The contents were mixed immediately. The 
reaction was allowed to proceed for 30 minutes at room temperature and each 
tube was subsequently monitored at 660 nm. The protein content of the unknown 
sample was determined by using bovine serum albumin to construct a standard 
calibration curve. 
(B) Protein estimation by the Bradford method: 
This method is based on strong binding of the dye Coomassie Brilliant Blue G-
250, in acidic medium, to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color develops (Amax-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution 
was diluted to a final volume of 1.0 litre and filtered through Whatman No. 1 filter 
paper to remove undissolved particles. 
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Procedure: 
To 1.0 ml of solution containing 10-100 pg protein was added 5.0 ml of dye 
solution. The contents were mixed thoroughly by vortexing. The abaorbance was 
read at 595 nm after 5 minutes against a reagent blank. 
Polyacrylamide gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing conditions 
as described by Laemmli (1970) (data not shown as serum samples from 
patients were analyzed in comparison to normal controls for preliminary 
experiments). 
Reagents: 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% bisacrylamide was prepared 
by dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a total volume 
of 100 ml. The solution was stored at 4°C in an amber coloured bottle. 
(il) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of 1 N 
HCI. The contents were mixed, pH adjusted to 8.8 and the final volume brought 
to 100 mi with distilled water. 
(lil) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 1 
N HCI and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and the final volume made up to 1.0 litre with distilled water. 
(v) Sample buffer 
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(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH adjusted 
to 6.8 with phosphoric acid. The final volume was brought to 100 ml 
with distilled water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 
12.5 ml of the above solution, p-mercaptoethanol was added just 
before use. 
Recipe for 10-20% Gradient Gel 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
20% 
10 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
20% 
10 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
The final volume was raised to 15 ml each with distilled water. 
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2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 Ml 
75 Ml 
25 Ml 
The final volume was raised to 10 ml with distilled water. 
Recipe for 7.5% SDS-PAGE (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
2.5 ml 
2.5 ml 
100 Ml 
50 Ml 
10 Ml 
The final volume was raised to 10 ml with distilled water. 
Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly 
washed with tap water followed by a final rinse with distilled water and ethanol. 
The plates were dried and sealed with 1% agarose and 1.5 mm thick spacers. 
The reagents were mixed and poured between the glass plates. The resolving 
gel was allowed to polymerize at room temperature, following which, the stacking 
gel was layered on top. A well-forming comb was inserted immediately and the 
gel was left to polymerize at room temperature. In case of gradient gels, a 
gradient of resolving gel was formed with the help of a gradient former (Blo-Rad, 
model 385). After ensuring complete polymerization, the protein samples (25-
100 pg) in one-fourth volume of sample buffer were electrophoresed at 80 volts 
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at room temperature. The gels were stained using 0.25% Coomassie Brilliant 
Blue R-250 or with silver stain reagent. 
Silver staining: 
Silver staining was done by the method of Merril et al. (1983). Briefly, the gel was 
incubated in 40% methanol and 12% acetic acid for 45 minutes followed by 
incubation in 50% ethanol for 30 minutes. Next the gel was treated with 0.02% 
hypo (sodium thiosulphate) for 1 minute. After washing with distilled water, the 
gel was placed in 0.2% silver nitrate (with 0.05% v/v formaldehyde), washed 
again with distilled water, and transferred to a 6% solution of sodium carbonate 
(with 0.05% v/v formaldehyde). After colour development, the gel was washed 
with distilled water and treating the gel with 3% v/v acetic acid and 5% v/v 
methanol arrested the reaction. All the reagents used in this procedure were 
freshly prepared. 
Agarose gel electrophoresis: 
Agarose gel was prepared by bringing 2% agarose to molten state in 
electrophoresis buffer (0.04 M Tris acetate, pH 8.0 containing 0.002 M EDTA). 
Molten agarose was poured on the gel tray and allowed to solidify for 1 hour at 
room temperature. The nucleic acid samples in one-tenth volume of stop-mix 
(30% ficoll, 0.025% xylene cyanole FF and 500 mM EDTA in 10X TAB buffer) 
were electropheresed for 2-4 hours at 30 mA in the same buffer. The gel was 
stained with ethidium bromide (0.5 pg/ml). 
Isolation of IgG by affinity chromatography: 
Protein A sepharose CL-4B was employed as the affinity matrix. It was swelled 
in 10 mM PBS, pH 7.4 at room temperature for 12 hours. The swelled matrix 
was washed with PBS and packed in a column having a dimension of 0.9 cm x 5 
cm. The packed column was washed with 0.1 M sodium citrate, pH 3.0 in order 
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to elute any bound material. This was followed by equilibration of the packed 
matrix with 5 volumes of PBS, pH 7.4. Serum diluted with equal volume of PBS, 
pH 7.4 was loaded onto ihe column and allowed to bind at a flow rale of 20 
ml/hour. Unbound protein was eliminated with PBS and absorbance of the 
effluent monitored till a negative absorbance was obtained at 280 nm. The 
bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride. To 
prevent the effect of acidic elution buffer on IgG, fractions were collected in 1 M 
Tris-HCI, pH 8.5. The fractions containing IgG were monitored at 280 nm. The 
IgG concentration was determined considering 1.4 OD280 = 1.0 mg IgG/ml. The 
isolated IgG was dialyzed against 10 mM PBS, pH 7.4 and stored at -20°C with 
0.1% sodium azide. To check the purity of IgG, the samples were subjected to 
7.5% SDS-PAGE. 
Gel retardation assay: 
The binding of TB-IgG with M. tuberculosis sonic extract proteins as well as with 
MTCF proteins was analyzed by altered electrophoretic mobility on SDS-PAGE 
under non-reducing conditions. M. tuberculosis proteins were allowed to interact 
wit;. TB-IgG for 2 hours at 37°C and overnight at 4°C. This resulted in the 
fonnation of immune complex (IC). Thereafter, the complex was electrophoresed 
on 7% SDS-PAGE under non-reducing conditions for 2 hours at 80 V. The 
electrophoresed gels were visualized by staining with 0.25% Coomassie Brilliant 
Blue R-250. 
Enzyme-linked immunosorbent assay (ELiSA): 
Antibodies were detected and quantified by ELISA using polystyrene flat-bottom 
microtitre plates as solid phase. The method described by Alam et al (1992) and 
Islam and AN (1998) was followed for the assay. 
Buffers and reagents: 
(i) Tris-buffered saline (TBS) 
10 mM Tris, 150 mM NaCI, pH 7.4 
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(ii) Tris-buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCI, 2.68 mM KCI and 1.0 ml/litre Tween-20, 
pH7.4 
(iii) Bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6 
(iv) Substrate buffer (for anti-liuman IgG alkaline phosphatase 
conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 2 mM 
magnesium chloride, pH 9.6 
Substrate: 0.5 mg/ml of p-nitrophenyi phosphate 
(A) Direct binding ELISA: 
Polystyrene microtitre plates were incubated with 100 pi of protein antigen (30 
|jg/ml in carbonate/bicarbonate buffer, pH 9.6) for two hours at room temperature 
followed by overnight incubation at 4°C. The plates were washed thrice with 
TBS-T and unoccupied sites blocked by 150 [i\ of BSA (1.5% in TBS, pH 7.4) for 
4-6 hours at room temperature. Serially diluted sera in TBS were added to 
antigen-coated as well as control (antigen uncoated) wells. The antigen-antibody 
interaction was allowed to proceed for two hours at room temperature followed 
by overnight incubation at 4°C and subsequently the plates were washed four 
times with TBS-T in order to remove the unbound antibodies. Bound antibodies 
were assayed by means of appropriate anti-immunoglobulin alkaline 
phosphatase conjugate using p-NPP as substrate. The reaction was stopped 
with 3 N NaOH and the absorbance of each well was monitored at 405 nm 
on an ELISA microplate reader. Each sample was coated in duplicate and 
the results were expressed as a mean of Atesi - Acontroi-
(B) Inhibition ELISA: 
The antigen binding specificity of antibody was determined by inhibition 
experiments (Hasan et ai., 1991). Varying concentration of inhibitors (0-20 
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|jg/ml) were mixed with a constant amount of antiserum or IgG. The mixture was 
incubated for two hours at 37°C followed by overnight incubation at 4°C. The 
resulting immune complex was employed in the immunoassay instead of serum. 
The rest of the steps were as in direct binding ELISA. The results were 
expressed as percent inhibition. 
r^(nhibited 
Percent inhibition = (1 )x100 
'^uninhibited 
Preparation of mycobacteria: 
Virulent laboratory-adapted M. tuberculosis (H37Rv) were grown in Middlebrook 
7H9 broth supplemented with Middlebrook ADC enrichment fluid at 37°C in 5% 
CO2. Mycobacterial cultures were harvested at midlogarithmic (14 days) phase. 
Aliquots of the stock were kept at -70°C until use. The viability of the stock 
remained >99% at 1 year. Before use, aliquots were defrosted, then vortexed 
with glass beads for 15 minutes, followed by equilibration at 37°C for 45 minutes. 
This treatment results in single cell suspension of mycobacteria (Toossi et al., 
1996). 
Isolation of mycobacterial antigens: 
Midlogarithmic mycobacterial cultures (14 days) were heat-killed at 100°C for one 
hour in a boiling water bath, followed by centrifugation at 10,000 rpm for 30 
minutes at 4°C. The culture filtrate containing secreted proteins was separated 
and stored at -20°C until further use. 
(A) Desalting of M. tuberculosis culture filtrate (MTCF) proteins: 
The supernatant was sterilized by filtration through a 0.22 micron pore size 
membrane (Millipore Corp., USA). MTCF was concentrated 50 fold by 
41 
ammonium sulphate and dialyzed against 10 mlVI PBS, pH 7.4 for desalting. The 
protein content was determined by the method of Lowry et al. (1951) against a 
BSA standard. The culture filtrate preparations were stored in small aliquots at -
20°C. 
(B) M. tuberculosis sonic extract (MTSE) proteins: 
Heat-killed bacilli were washed with sterile TBS, pH 7.4 and suspended in 
sonicating buffer containing 1 mM DTT, 1 mM PMSF, 1.0 pl/mi p-
mercaptoethanol and proteinase inhibitors cocktail in TBS, pH 7.4. Sonicating at 
4°C for 15 minutes in a sonicator disrupted the cell suspension and the cell 
debris was removed by ultra centrifugation at 20,000 rpm for 15 minutes. The 
protein content was determined by the method of Lowry et al. (1951). The sonic 
extract preparations were stored at-20°C in small aliquots until required. 
Preparation of RPMI-1640 medium: 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) was suspended in 950 
ml of tissue culture-grade water at room temperature with constant, gentle stirring 
until the medium was completely dissolved. The container was rinsed with tissue 
culture grade water to remove all traces of powder and added to the above 
solution. 3.7 gm sodium bicarbonate was added to the medium and stirred until 
dissolved. The final volume was brought to 1000 ml with tissue culture grade 
water. The medium was sterilized immediately by filtering through a sterile 
membrane filter with a porosity of 0.22 micron using positive pressure rather than 
vacuum to minimize the loss of carbon dioxide, and stored at 4°C till use. 
Preparation of PBIVIC: 
Step 1: In order to isolate peripheral blood mononuclear cells (PBMCs), 60 ml of 
blood was drawn from a healthy volunteer into 60 cm^ syringes containing 
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3.8 units heparin/ml. The heparinized blood, in 15 ml aliquots, was 
transferred to stenle 50 ml polypropylene centrifuge tubes and diluted 1:1 
with sterile 10 mM, PBS, pH 7.4 at room temperature, followed by gentle 
mixing by inverting the tube a few times. 
Step 2: Diluted blood was under layered with 15 ml of Ficoll-Paque at room 
temperature using an 18 gauge spinal needle. Care was taken to prevent 
mixing of ffre layers. ThQ gradient was centrifuged at 1800 rpm for 30 
minutes at room temperature with the centrifuge brake turned off. 
Step 3: Using a sterile pipette, the upper clear layer containing plasma was 
removed. The PBMCs appeared as a dense white band (buffy layer) 
above the red blood cells and granulocytes layer. This was removed with 
another sterile pipette. The banded cells were combined in 10 ml aliquots. 
Step 4: Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in sterile 
50 ml polypropylene centrifuge tubes and centrifuged at 1100 rpm for 12 
minutes at room temperature to remove platelets, which remain in the 
supernatant. The PBMC pellets were combined to four tubes, diluted in 30 
ml PBS and centrifuged at 1100 rpm for 10 minutes at room temperature. 
This wash was repeated. 
Step 5: The pellets were then combined and resuspended in 30 ml complete 
medium (CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 mM 
HEPES, and no antibiotics). An aliquot was diluted 20-fold and counted 
using a hemocytometer under a light microscope using lOx ocular and 40x 
objective. 
Preparation of autologous serum for monocyte culture: 
From the same donor 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at least 
30 minutes, then centrifuged at 3000 rpm for 15 m'mutes at room temperature 
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and the serum filtered through a sterile 0.22 pm filter unit. Autologous serum can 
be stored for a year or longer at -20°C. 
Cell culture: 
PBMCs (5x10^ cells/well) were added in 12-wells tissue culture plates in 
complete RPMI-1640 medium, and were subsequently incubated at 37°C, 5% 
CO2 for 1-2 hours for adherence. Thereafter, non-adherent cells were removed 
by washing the plates extensively 4 times with RPMI-1640 medium. The 
adherent monocytes were cultured in RPMI-1640 supplemented with 2% 
autologous serum, followed by overnight resting at 37X, 5% CO2. This 
population of adherent cells is up to 95% monocytes, as observed by 
cytostaining and is 39% viable (Toossi et al., 1996). Prior to infection, the plates 
were washed twice with RPMI-1640 medium. 
Infection and co-culture of monocytes with supplements: 
Healthy monocytes were infected with M. tuberculosis (H37RV) at 1:1 
(bacteria/cell) in 30% autologous unheated serum for 90 minutes at 37°C, 5% 
CO2. Subsequent to this, the infected monocytes were washed four times with 
complete medium. Cells harvested at this time point were considered as time 
zero after infection (to). Other cultures received RPMI-1640 medium with 2% 
autologous serum. As per experimental design, some cultures, immediately after 
infection received 10 ng/ml anti-TNF-a antibodies, varying doses of EGCG (0-25 
ng/ml), 10 nM reduced glutathione. 10 mM NAC, 100 pg/ml SN50 and SN50/M. 
Cultures were then harvested after 24 hours and cells were lysed in 0.5 ml of 
TRIZOL Reagent (Invitrogen Inc. Carlsbad, CA, USA) for RNA extraction or in 
protein lysate buffer for other studies. The cell-free culture supernatants were kept 
at-70°C. 
Treatment with EGCG monocytes viability assay: 
The effect of EGCG (0-25 pg/ml) on the viability of monocytes from patients with 
SLE, TB and SLE-TB was assessed by using MTT Cell Viability Assay Kit (R&D 
Systems) according to the manufacture's instructions provided. 
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Reagents supplied in the kit: 
Component Quantity Storage conditions 
MTT reagent 25 ml 2 -8°C 
Detergent reagent 250 ml 18-24°C 
Assay procedure: 
Adherent monocytes were gently scraped with RPMI-1640 medium. After this, 
monocytes (3 x 10"* cells/well in 100 pi) were added in 96-well tissue culture 
plates. Cells were incubated in RPMI-1640 with 2% autologous serum containing 
varying doses of EGCG for 24 hours at 37°C, 5% CO2. After 24 hours, 10 pi of 
MTT reagent (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was 
added to each well and incubation was continued for an additional two hours. 
When a purple precipitate was clearly visible under the microscope, 100 pi of 
detergent reagent was added to all wells, including control wells and incubated for 
two hours in the dark at 20''C. After incubation, the precipitate was solubilized and 
the absorbance of the resulting solution was measured at 570 nm using a 
microplate reader. Control cells were treated exactly the same except that no 
EGCG added to the wells. The percentage of viable cells was calculated by the 
fomnula as described by Islam et al. (2000) and the results are expressed as 
"Viable cells (% of control cells)". 
Viable monocytes (% of control cells) = 
Absorbance value of control cells 
Absorbance value of treated cells 
x100 
Trypan blue exclusion assay for monocytes viability: 
Adherent monocytes were gently scraped with RPMI-1640 medium. Trypan blue 
suspension (1.6 mg/ml in saline solution) was added to the monocytes at a final 
concentration of 0.8 mg/ml. The cells were kept at ST^C for 7 minutes in a CO2 
chamber (5%), mounted on a hemocytometer and then observed under light 
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microscope. The cells taking up Trypan blue (dead cells), and cells excluding the 
dye (viable cells) were counted. Percentage of viable cells was calculated by the 
following formula; 
Total viable cells (unstained) 
% Cell viability = x 100 
Total cells (stained plus unstained) 
TNF-a Immunoassay 
The concentration of TNF-a in various culture supernatants as well as in serum 
of patients was determined by use of a commercial ELISA Kit ( R & D Systems). 
This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for TNF-a was available pre-coated 
onto a microplate. Standards and samples were pipetted into the wells and the 
immobilized antibody bound any soluble TNF-a present. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for TNF- a 
was added to the wells. Following a wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells and colour 
developed in proportion to the amount of TNF-a bound in the initial step. The 
colour development was stopped and the intensity of the colour was measured. 
Reagents supplied in tlie kit: 
TNF-a microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated 
with a mouse monoclonal antibody against TNF-a. 
TNF-a conjugate - 21 ml of polyclonal antibody against TNF-a conjugated to 
horseradish peroxidase, with preservatives. 
TNF-a standard -10 ng of recombinant human TNF-a in a buffered protein base 
with preservatives, lyophilized. 
Assay diluent RD1F - 6 ml of a buffered protein base with preservatives. It 
contained a precipitate and was mixed well before and during use. 
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Calibrator diluent RD6-35 - 21 ml of animal serum with preservatives. 
Wash buffer concentrate - 21 mi of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B -12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution ' 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted into deionized or 
distilled water to prepare 500 ml of wash buffer. 
Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-35 was 
mixed with 80 ml of deionized or distilled water to yield 100 ml of diluted 
calibrator diluent RD6-35. 
Substrate solution - Colour reagents A and B were mixed together in equal 
volumes within 15 minutes of use to form substrate solution. It was protected 
from light. 
TNF-a standard - TNF-a standard was reconstituted with 1.0 ml of distilled 
water. This reconstitution produced a stock solution of 10,000 pg/ml. The 
standard was allowed to sit for a minimum of 15 minutes with gentle agitation 
prior to making dilutions. 
Assay procedure: 
50 pi of assay diluent RD1F was added to each well of 96 well polystyrene 
microplate coated with a mouse monoclonal antibody against TNF-a. Thereafter, 
200 pi of standards, samples, or control per well was added, covered with the 
adhesive strip provided and incubated for 2 hours at room temperature. The plate 
was washed four times by filling each well with wash buffer using a squirt bottle. 
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After washing, 200 pi of TNF-a conjugate was added to each well, covered with a 
new adhesive stnp and Incubated for 1 hour for cell culture supernatants and 2 
hours for serum Samples at room temperature. After four washings with wash 
buffer, 200 pi of substrate solution was added to each well and incubated for 20 
minutes at room temperature in the dark, a blue colour appeared. Thereafter, 50 
pi of stop solution was added to each well to stop the reaction. Then the 
absorbance of each well was determined within 30 minutes, using a microplate 
reader set to 450 nm. The cut off or lower limit of sensitivity was 4.4 pg/ml. 
Glutathione peroxidase assay 
The activity of glutathion<3 peroxidase (GPx) was measured as described 
elsewhere (Mohandas et al., 1984; Mates et al., 1999). The oxidized glutathione 
(GSSG) produced during GPx reaction was immediately reduced by NADPH and 
glutathione reductase. Therefore, the rate of NADPH consumption was regarded 
as the rate of GSSG formation during the GPx reaction. Patients as well as 
healthy control monocytes were co-cultured for 24 hours with or without 10 mM 
NAC. 100 pg/mf SN50, 100 pg/ml SN50/M and 0-25 ug/ml EGCG. Thereafter, 
cells were gently scraped with lysis buffer containing protease inhibitors (50 mM 
Tris/HCI, pH 7.4; 1 mM EDTA; 500 mM PMSF). The cell suspension was 
homogenized with a sonicator on ice and centrifuged at 10,000 rpm for 10 
minutes. Protein concentrations of supernatants were determined by the method 
of Bradford with BSA as the standard, and were subjected to GPx activity 
determination. The reaction mixture (1.0 ml) containing 50 mM potassium 
phosphate (pH 7.0), 1 mM sodium azide, 2 mM GSH, 0.2 mM NADPH, 1 unit/ml 
glutathione reductase, 1.5 mM cumene hydroperoxide, and 20-100 pi of samples 
were incubated at 25''C for 5 minutes. The reaction was initiated by the addition 
of cumene hydroperoxide. The kinetic change was spectrophotometrically 
recorded at 340 nm (37°C) for 3 minutes. GPx activity was calculated after 
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subtraction of the blank value, as pmol of NADPH oxidized/mlnute/mg protein 
(U/mg protein). 
IntraiTionocyte Glutathione Assay. 
Glutathione (GSH) levels in treated or control monocytes were assayed by 
spectrophotometry, using a GSH assay kit (Calbiochem) as previously described 
by us (Hasan et al., 2007). Monocytes were mixed with equal volume of ice cold 
5% metaphosphoric acid and centrifuged at 3000 rpm for 15 min. Supernatants 
were used for GSH assay, as per the manufacturer's instruction. 
Assay for Malondialdehyde (MDA) levels. 
As a matter of fact, free radicals, because of their unstable and transient nature 
are difficult to measure directly. Their tendency to cause lipid peroxidation has 
been used as an indirect measure. Hence estimation of lipid peroxides (markers 
of lipid peroxidation), was carried out by measuring MDA (Malondialdehyde) as 
described earlier (Philpot, 1963). 
Principle: One Molecule of MDA reacts stoichiometrically with two molecules of 
thiobarbituric acid (TBA) at pH 3.5. The pink color chromogen can be measured 
spectrophotometrically at 532 nm. 
Procedure: For assay 1 ml of serum was mixed with 2.5 ml of 20% 
trichloroacetic acid (TCA) and 1 ml of 0.67% of aqueous solution of TBA. The 
mixture was heated for30 minutes in boiling water bath, the pink pigment was 
extracted with 2 ml of n-Butanol and Its absorbance was read at 532 nm against 
n-butonol as blank: 
MDA——^J^^^P^ X Cone, of standard MDA 
ODofs tan dara 
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RNA extraction 
After lysis of monuoytes in 0.5 ml TRIZOL Reagent, the cell lysates were agitated 
with glass beads to complete cell wall disruption. After cooling on ice the tubes 
were again subjected to repeated disruption as above. The tubes were cooled 
and 200 pi of chloroform was added to each sample, followed by vortexing for 2 
minutes, and centrifugation at 3000 rpm for 5 minutes. Samples were then 
transferred to fresh eppendorf tubes and centrifuged at 14,000 rpm for 15 
minutes at 4°C. The aqueous layer was harvested and transferred to a fresh 
tube. After addition of 100 pi Cleanascite (CPG Inc., Lincoln Park, NJ, USA), 
samples were gently rocked for 10 minutes and then centrifuged at 14,000 rpm 
for one minute. The aquecus layer obtained was mixed with 500 pi of chloroform-
isoamyl alcohol (24:1) and vortexed. RNA was precipitated using 50 pi of 1 M 
sodium acetate, and 475 pi of isopropanol at -20°C for 3 hours in the presence 
of glycogen. This was followed by centrifugation at 14,000 rpm and the pellet 
obtained was washed two times with 75% ethanol, and resuspended in 87 pi 
DEPC-water. DNAase 1 digestion (10 pi of 10X DNAse 1 buffer in 0.5 M Tris pH 
7.5, 0.1 M MgCl2, 1 mM DTT; and 50 pg/ml BSA, 2.0 pi RNAase inhibitor; 10U 
RNAase free DNAase 1) was employed to remove DNA. The reaction was 
stopped by the addition of 700 pi of 0.5 M NH4OAC and the RNA was re-
extracted using 500 pi of acid phenol-chloroform (1:1). The aqueous layer was 
harvested, extracted again with chloroform-isoamyl alcohol and precipitated. 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
The DNAase-treated RNA was subjected to reverse transcription using oligo(dT) 
primers with Superscript 11 reverse transcriptase (Invitrogen, Life Technologies, 
USA) according to the manufacturer's instructions. RNA (2 pg) was transcribed 
into cDNA in a 20 pi reaction volume containing 50 mM Tris-HCI, pH 8.3, 75 mM 
KCI, 3 mM MgCl2, 10 mM DTT, 0.5 mM of each deoxynucleotide triphosphate, 25 
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pg/ml oligo(dT)i2-i8 primers and 10 \JI[}\ of Superscript II reverse transcriptase, at 
42°C for 50 minutes. The reaction was then stopped by heating at 70°C for 15 
minutes followed by rapid chilling on ice. 
PCR: The primers used as described by our laboratory previously (Hasan et al., 
2006). cDNA for 3-actin was amplified with various primer sets supplied by 
(Stratagene, La Jolla, CA, USA). For PCR, 2.0 \i\ of each cDNA sample was 
used as template in the PCR amplification. The reactions were carried out in a 50 
pi reaction volume containing 20 mM Tris-HCI, pH 8.4, 50 mM KCI, 1.5 mM 
MgCl2, 0.2 mM of each of the four dNTPs, 2U of Taq DNA polymerase 
(Invitrogen) and 0.2 pM of each fonward and reverse primers. After initial 
denaturation for 2 minutes at 95°C, 35 cycles at 95°C for 15 seconds, 60°C for 
45 seconds were performed, followed by 72°C for 1 minute. The reaction 
products were visualized by electrophoresis in 2% agarose after staining with 0.5 
pg/ml ethidium bromide. 
Quantitative real-time RT-PCR: 
Real-time quantitative reverse transcriptase PCR (RT-PCR), which is the latest 
innovation in the field of PCR technology, provides a sensitive, reproducible, and 
accurate method for determining mRNA levels in tissues or cells. The method is 
based on the detection of a fluorescent signal produced and monitored during the 
amplificafion process, without the need for post-PCR processing (Heid et al., 
1996). 
Two important findings led to the discovery of real-time PCR. First, the Taq 
polymerase has a 5-3' exonuclease activity (Holland et al., 1991). apart from its 
polymerase activity. Second, dual-labelled fluorogenic oligonucleotide probes 
have been created which emit a fluorescent signal only upon cleavage, based on 
the principle of fluorescence resonance energy transfer (Cardullo et al., 1988). In 
the TaqMan assay (Applied Biosystems, Foster City, CA, USA), these two 
principles are combined. In this system a probe, the so-called TaqMan probe, is 
designed to anneal to the target sequence between the classical forward and 
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reverse primers. The probe is dually labelled, with a reporter fluorochrome (eg., 
5-carbofluorescein, or FAM) at one end and a quencher dye (eg., N,N,N',N'-
ietidmethyl-6-carborhodamine, or TAMRA) at the other end. In the intact probe, 
the fluorescence emission of the reporter dye will be absorbed by the quencher 
dye. The probe will be degraded during the extension phase by the 5-3' 
exonuclease activity of the Taq polymerase, separating the reporter and 
quencher, thus resulting in an increase in reporter fluorescence emission. The 
amount of fluorescence released is directly proportional to the amount of product 
generated in each PCR cycle and thus can be applied as a quantitative measure 
of PCR product formation. 
Procedure: 
Internal fluorescent hybridization probes were used in ABI Prism 7700 Detection 
System (ABI/PerkinElmer (PE) Biosystems, Foster City, CA, USA), which allows 
the sensitive and specific quantification of individual host (Hartel et al., 1999), as 
well as M. tuberculosis RNA, transcripts (Wilkinson et ai., 2001) by quantitative 
real-time RT-PCR. TaqMan™ PCR primers and probes as well as target-specific 
RT primer for each assay were designed as described elsewhere (Wilkinson et 
al., 2001; Islam et al., 2004). We have reported the primer and probe sequences 
used for R18, TNF-alpha and iNOS earlier (Islam et al., 2004, Hasan et. al., 
2006; Singh et al., 2002), and are also given below. All probes were dually 
labeled with FAM at the 5' end and TAMRA at the 3' end. The proximity of the 
dye (FAM) and the quencher (TAMRA) on the intact probe prevents detection of 
any fluorescence. However, degradation of the probe during the course of PCR 
allows the release and detection of FAM (Holland et al., 1991). The primer and 
probe sequences used for R18, TNF-alpha and iNOS were as given below: 
R18: 
RT primer: GACGGTATCTGATC; 
reverse primer: 5'-CAT TCT TGG CAA ATG CTT TC-3'; 
forward primer: 5'-CGC CGC TAG AGG TGA AAT TC-3'; 
TaqMan probe: 5'-6FAM-ACC GGC GCA AGA CGG ACC AGA-TAMRA-3'. 
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TNF-alpha: 
RT primer: GGTTTCTACAACA; 
reverse primor: 5'-GTTCGAGAAGATGATCTGACTGCC-3'; 
forward primer: 5'-AGGCGGTGCTTGTTCCTCA-3'; 
TaqMan probe: 5'-6FAM-CCAGAGGGAAGAGTTCCCCAGGGAC-TAMRA-3'. 
iNOS: 
RT primer: s'-CTCTggTCAAAC-S'; 
forward primer: s'-AgCggg-ATgACTTTCCAAgA-S'; 
reverse primer: S'-ATAATggACCCCAgg-CAAgATT-S' 
TaqMan Probe: S'-AMCCATAAggCCAAAgggATTTTAACTTgCAg-S' 
The PCRs for all amplifications were similar: 5 \^\ of each cDNA, 20 pi of Taqman 
Universal PCR Master Mix (PE Biosystems), which contains optimal amount-^  of 
AmpliTaq Gold DNA polymerase (which protects against amplicon carryover) and 
of dNTPs, and optimal amounts of probe and primers calibrated to allow 
measurement of the targets. First, cDNA was synthesized in the presence of 0.5 
pi of murine leukemia virus enzyme (Invitrogen, USA)/reaction and 10 pM each 
RT primer, dNTPs, and other substrate. Conditions for PCR were similar for all 
products (1 cycle of 2 minutes at 50°C and 1 cycle of 10 minutes at 95°C and 
then 40 cycles of 15 seconds at 95°C and 1 minute at 60°C). The cycle threshold 
for each sample was compared with the cycle threshold values of known 
amounts of a standard DNA constructed for each target and amplified 
simultaneously. To assure lack of DNA contamination in the RNA samples, in 
some experiments, a duplicate tube of sample with no RT enzyme was included 
as control. DNA contamination remained negligible. In each sample, host 18S 
ribosomal RNA was used as the internal control. Expression of TNF-a mRNA and 
iNOS were corrected to internal control (host 18S rRNA) in the same sample and 
was expressed as copies of TNF-a or iNOS in 10^° copies of R18 (equivalent to 1 
x 10^ monocytes). 
statistical analysis: 
Results were analyzed by paired t-test and the data expressed as mean ± SEM 
of six to eight experiments unless otherwise specified. P<0.05 was considered 
statistically significant. 
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RESULTS 
The present study was carried out in four distinct parts - (I) evaluation of clinical 
profile of patients whose blood or serum were undertaken in this study was 
carried out, (II) characterization of monocytes from patients with SLE, TB and 
SLE-TB whose untreated / treated monocytes in turn would be utilized as 
valuable immuno-reagents, (III) regulation / modulation of above monocytes and 
(IV) immunological investigations of the above characterized / modulated 
monocytes and clinically evaluated sera's. 
Thus, first of all, prior to any study, evaluation of clinical profile of patients whose 
blood or serum were undertaken in this study was carried out, which are 
described as under: 
(I): CLINICAL PROFILE OF PATIENTS 
A. Classification of patients 
A total of 100 subjects were selected for clinical evaluation, where 10 were 
healthy normal subjects that served as controls. The remaining ninety study 
group patients (100%) comprised of 30 SLE patients (33.3%), 30 TB patients 
(33.3) and 30 SLE-TB patients (33.3%). 
B. Distribution of sex in clinically classified patients 
Next, the patients and control subjects undertaken in this study were distributed 
with respect to sex. Thus, out of 10 healthy normal subjects, 5 were males (50%) 
and 5 females (50%). The 30 SLE patients comprised of 10 males (33.3%) and 
20 females (66.6%). Similarly, out of 30 TB patients, 10 were males (33.3%) and 
20 females (66.6%). The same is true for SLE-TB patients, where out of 30 such 
patients, 10 were males (33.3%) and 20 were females (66.6%). 
C. Distribution of Age 
The above clinically classified patients were of 4 age groups, and are 
summarized in Table 3. Briefly, the 4 types of age groups were: Group 1= 20-35 
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yrs, Group 2 = 36-50 yrs, Group 3 = 51-65 yrs and Group 4 = 66-80 yrs. In 
control subjects, 20% subjects were from age group 1, whereas 30% each were 
from age group 2 and 3 respectively. Finally, there were 20% suojects from age 
group 4. 
D. Montoux Test 
The initial detection of TB infection was detected by Montoux test. The following 
Table IV shows the distribution of Montoux Test (+ve/-ve) in control, TB and SLE-
TB patients. None of the healthy control subjects or SLE patients responded 
towards Montoux test. On the contrary, 100% TB patients as well as SLE-TB 
selected in this study showed a positive Montoux test. The observation of 
positive Montoux test in TB and SLE-TB patients selected in this study indicates 
the presence of bacilli infection in the selected host. The distribution of Montoux 
test is depicted in Table 1. 
TABLE I 
Distribution of Montoux Test in control, TB, SLE and SLE-TB patients 
Groups 
Normal 
control 
SLE 
TB 
SLE-TB 
healthy 
No. of cases 
10 
30 
30 
30 
Positive 
Nil 
Nil 
30(100%) 
30 (100%) 
IVIontoux Test 
Negative 
10(100%) 
30(100%) 
Nil 
Nil 
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E. Blood Glucose fevefs fn SLE, TB and SLE-TB patients 
All the patients and control samples undertaken In this study were subjected to 
evaluation of blood glucose levels. Healthy normal subjects showed norma! blood 
glucose levels. Interestingly, 16% SLE patients of age group 51-65 yrs (both sex) 
exhibited an slightly augmented blood glucose level (mean range: 167-183 
mg%). Similarly, 19% TB patients of age group 66-80 yrs showed to have 
elevated blood glucose (mean range: 171-187 mg%). Also, 20% patients having 
both SLE along with TB (SLE-TB) in the age group of 51-65 yrs and 66-80 yrs 
showed an enhanced blood glucose level falling under the mean range of 173-
193 mg/%. 
F. Distribution of Anti-dsDNA 
Direct binding ELISA analyzed patients and control samples undertaken in this 
study for anti-dsDNA evaluation. The observations made are summarized in 
Table VI. Healthy normal subjects showed negative anti-dsDNA results as the 
titre of anti-dsDNA was found to be less that 1:100. It is to be pointed out here 
that any anti-dsDNA titre, which is equal to or greater than 1:1600, is considered 
to be positive. Similarly, all the TB patients selected in this study exhibited an 
anti-dsDNA titer of <1:800, thereby suggesting for the fact that none of the TB 
patient's sera had any anti-dsDNA antibody in it. On the contrary, both SLE and 
SLE-TB patient's sera showed an anti-dsDNA titre that was greater than 
1:128000. thereby indicating for the presence of high titer of anti-DNA 
autoantibodies (P<0.001). 
G. Chest X-Ray 
SLE patients had no evidence of cavity formation/fluffy shadow on chest X-ray to 
suggest pulmonary kochs. On the contrary, both TB and TB-SLE groups of 
patients exhibited pulmonary kochs. The summary is depicted below in Table II 
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TABLE - II 
Dlsiributlon of Chest X-ray In TB, SLE-TB and SLE pati«=.)ts 
Groups 
Normal Control 
TB 
TB-SLE 
SLE 
Cases 
No 
10 
30 
30 
30 
%Age 
100 
33.3 
33.3 
33.3 
Chest X-ray 
Mean observation 
No cavity / fluffy shadow 
Cavity/fluffy shadow in all cases 
Cavity/fluffy shadow in all cases 
No cavity/fluffy shadow 
(II) CHARACTERIZATION OF MONOCYTES FROM NORMAL HEALTHY AND 
PATIENTS WITH SLE, TB AND SLE-TB: 
1. Comparative study on the human housekeeping gene of human 
monocytes from normal controls versus patient with SLE, TB and SLE-TB: 
Prior to any investigation, an attempt was made to probe the adverse effect of 
disease activity in monocytes of patients with SLE (n=3; P<0.001), TB (n=3; 
P<0.001) and SLE-TB (n=3; P<0.001) in comparison to normal healthy controls 
(n=3), if any, on the human housekeeping gene. It was observed that disease 
activity in 24 hr monocyte cultures failed to exert any adverse effect on the host 
housekeeping genes like R18 gene (18S rRNA) as revealed by quantitative real-
time RT-PCR (Fig. 1). 
2. Basal levels of TNF-a expressions at the gene and protein levels in 24 hr 
monocyte cultures from normal healthy controls and patients with SLE, TB 
and SLE-TB. 
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Thereafter, we investigated the basal levels of TNF-a mRNA expressions in 24 hr 
monocyte cultures from normal healthy controls (n=8) and patients with SLE 
(n=8) TB (n=8) and SLE-TB (n=8). TNF-a mRNA was corrected to host internal 
control, i.e., 18S rRNA, in the same sample. As evident from Fig. 2, the basal 
levels of TNF-a mRNA copy numbers In patients with SLE, TB and SLE-TB were 
recorded as 6.6 logs (P<0.001), 6.3 logs (P<0.001) and 7.7 logs (P<0.001) 
respectively. No or negligible TNF-a mRNA expression was observed in normal 
healthy controls (Fig. 2). 
Thus, the magnitude of TNF-a mRNA expression in monocytes was of the order 
of SLE-TB > SLE > TB patients respectively. 
Next, we further probed the basal secreted TNF-a expressions in culture 
supernatants of the above monocyte cultures that were harvested after 24 hrs. 
As evident from Fig. 3, the concentration of soluble TNF-a secreted in 
supernatants was observed as 194.3 (P<0.001), 183.2 (P<0.001) and 221.2 
(P<0.001) pg/ml from patients with SLE (n=8), TB (n=8) and SLE-TB (n=8) 
respectively. Again, no or negligible TNF-a protein expression was observed in 
normal healthy controls (n=8) (Fig. 3). 
3. Basal levels of INOS mRNA expressions in 24 hr monocyte cultures from 
normal healthy controls and patients with SLE, TB and SLE-TB. 
Next, we investigated the basal levels of iNOS mRNA expressions in 24 hr 
monocyte cultures from normal healthy controls (n=8) and patients with SLE 
(n=8) TB (n=8) and SLE-TB (n=8). iNOS mRNA was corrected to host internal 
control, i.e., 18S rRNA, in the same sample. As evident from Fig. 4, the basal 
levels of iNOS mRNA copy numbers in patients with SLE, TB and SLE-TB were 
recorded as 5.3 logs (P<0.001), 5.4 logs (P<0.001) and 5.9 logs (P<0.001) 
respectively. No or negligible iNOS mRNA expression was observed in normal 
healthy controls (Fig. 4). Thus, the magnitude of iNOS mRNA expression in 
monocytes was of the order of SLE-TB > SLE > TB patients respectively. 
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4. Basal levels secreted IFN-y protein expressions in 24 hr monocyte 
cultures from normal healthy controls and patients with SLE, TB and SLE-
TB. 
Next, we further probed the basal secreted IFN-y expressions in culture 
supernatants of the above monocyte cultures that were harvested after 24 hrs. In 
comparison to normal healthy control cultures (167.85 pg/ml), the concentration 
of soluble IFN-y was found to be down-regulated to 43.56 (P<0.001), 41.23 
(P<0.001) and 38.26 (P<0.001) pg/ml in cultures from patients with SLE (n=8), 
TB (n=8) and SLE-TB (n=8) respectively (Fig. 5). 
5. Glutathione peroxidase (GPx) activity in 24 hr monocyte cultures from 
normal healthy controls and patients with SLE, TB and SLE-TB. 
Next, an attempt was made to probe the glutathione peroxidase (GPx) activities 
in culture supernatants of the above monocyte cultures that were harvested after 
24 hrs. Normal healthy control cultures exhibited a GPx activity of 57.22 U/mg 
proteins (Fig. 6). As expected, GPx activities were suppressed to the order of 
29.25 (P<0.001), 25.14 (P<0.001) and 20.48 (P<0.001) U/mg protein in cultures 
from patients with SLE (n=8), TB (n=8) and SLE-TB (n=8) respectively (Fig. 6). 
(Ill) REGULATION STUDY: 
1. Dose response effect of NAC on the expressions of secreted TNF-a 
protein in 24 hr monocyte cultures from normal healthy controls and 
patients with SLE, TB and SLE-TB. 
Monocytes obtained from patients with SLE (n=3), TB (n=3) and SLE-TB (n=3) 
were co-cultured in RPMI-1640 media with varying doses of NAC (0-1C mM) for 
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24 hrs at 37C/5%C02 Thereafter, the cells were harvested and subjected to 
secreted TNF-a protein expression analysis by ELISA. As expected, normal 
healthy control cells failed to show any effect of NAC as no or negligible TNF-a 
was recorded in untreated cells. However, NAC exhibited an appreciable dose-
dependent suppression in secreted TNF-a protein expressions in 24 hr monocyte 
cultures from patients with SLE (n=3), TB (n=3) and SLE-TB (n=3) respectively 
(Fig. 7; P<0.001 for all three groups). 
2. Toxicity assessment of EGCG: 
Prior to probing the effect of EGCG, an attempt was made to check the toxic 
effect, if any, monocytes from patients with SLE (n=3), TB (n=3) and SLE-TB 
(n=3) respectively. For this purpose, we chose a dose in between 0 - 2 5 jjg/ml of 
EGCG (dose-response assay) as this dose has previously been established in 
our laboratory in healthy monocytes. The results depicted in Fig. 8 (P<0.001), 
failed to show any toxic effect of EGCG (0 - 25 pg/ml) on monocytes as revealed 
by MTT (Fig. 8) or trypan blue exclusion assays. Cell viability is expressed as 
percent (mean ± SEM) viable cells compared to untreated cells (taken as 100% 
viable). Also, no effect was observed on housekeeping genes like R18 (18S 
rRNA) by quantitative real-time RT-PCR (Fig. 9), thereby indicating that EGCG 
did not non-specifically affect human TNF-a transcription. 
3. Dose response effect of EGCG on the expressions of secreted TNF-a 
protein in 24 hr monocyte cultures from normal healthy controls and 
patients with SLE, TB and SLE-TB. 
Next, monocytes from patients with SLE (n=5), TB (n=5) and SLE-TB (n=5) were 
co-cultured with varying doses of EGCG (0-25 pg/ml) for 24 hrs at 37C/5%C02, 
After harvesting, the cells were subjected to analysis of secreted TNF-a protein 
expression by ELISA. 
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As expected, normal healthy control cells failed to show any effect of EGCG as 
no or negligible TNF-a was recorded in untreated cells. However, EGCG 
exhibited an appreciable dose-dependent suppression in TNF-a expressions in 
24 hr monocyte cultures from patients with SLE, TB and SLE-TB respectively 
(Fig. 10; P<0.001 for all). The IC50 was computed out to be ~ < 5 \^gl^^\\. 
4. Effect of SN50 and SN50M on the expressions of secreted TNF-a in 24 hr 
monocyte cultures from normal healthy controls and patients with SLE, TB 
and SLE-TB in order to probe the role of NF-KB: 
Induction of TNF-a as a consequence of cellular activation is mediated via NF-KB 
(Toossi et al., 1997; Fan et al., 2002, Hasan et al., P006). Reports indicate that 
TNF-a induced nuclear translocation of NF-KB was inhibited in SN50 peptide-
treated human monocytic cell lines as demonstrated in EMSA (Lin et al., 1995). In 
view of it, we employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB in 
activation of TNF-a protein expression in M. tuberculosis-mfected monocytes. 
SN50 (100 pg/ml) was added to monocytes 3 minutes prior to M. tuberculosis 
infection. Control cultures did not receive SN50. At 24 hours, SN50 suppressed 
secreted TNF-a protein expression by around 1.96-folds (i. e. suppressed from 
194.3 pg/mi to 98.9 pg/ml), 2.11-folds (i. e. suppressed from 183.2 pg/ml to 86.8 
pg/ml) and 2.04-folds (i. e. suppressed from 212.2 pg/ml to 103.6 pg/ml) in 24 hr 
monocyte cultures from patients with SLE (n=5; P<0.001), TB (n=5; P<0.001) 
and SLE-TB (n=5; P<0.001) respectively (Fig. 11). 
Furthemiore, in order to ensure that cellular inhibition was not non-specific, we 
compared the effect of SN50 with its Inactive analogue, SN50/M at the same 
concentration. SN50/M did not affect secreted TNF-a protein expression (P<0.001) 
(Fig. 11). Therefore, it can be inferred that the increased expression of TNF-a in 
24 hr monocyte cultures from patients with SLE, TB and SLE-TB respectively is 
mediated mainly via NF-KB. 
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5, Effect of NAC and EGCG on GPx activity In 24 hr monocyte cultures from 
normal healthy controls and patients with SLE, TB and SLE-TB. 
Next, an attempt was made to probe the modulatory effect of NAC and EGCG on 
glutathione peroxidase (GPx) activities in culture supernatants of the above 
monocyte cultures that were harvested after 24 hrs. As described above in Fig. 6, 
normal healthy control cultures exhibited a GPx activity of 57.22 U/mg proteins, 
whereas GPx activities were suppressed to the order of 29.25, 25.14 and 20.48 
U/mg proteins in cultures from patients with SLE (n=8), TB (n=8) and SLE-TB 
(n=B) respectively (Fig. 6). On the contrary, modulation with 10 mM NAC and 5 
pg/ml of EGCG showed interesting results. Thus, as evident from Fig. 12, NAC 
(10 mM) showed amelioration in GPx activities from 29.25, 25.14 and 20.48 
U/mg proteins to 44.23, 42.01 and 40.88 U/mg proteins in cultures from patients 
with SLE, TB and SLE-TB respectively (Fig. 12). Similarly, EGCG (5 [iglm\) 
exhibited showed amelioration in GPx activities from 29.25, 25.14 and 20.48 
U/mg proteins to 49.23, 46.01 and 45.88 U/mg proteins in cultures from patients 
with SLE, TB and SLE-TB respectively (Fig. 13) (P<0.001 for all). 
6, Determination of MDA levels in 24 hr culture filtrate of monocytes of 
patients with SLE, TB and SLE-TB 
Thereafter, an attempt was also made to evaluate the MDA levels in culture 
supernatants of 24 hr monocyte cultures from patients with SLE (n=3), TB (n=3) 
and SLE-TB (n=3) respectively. As shown in Fig. 14, normal healthy control (n=3) 
cultures exhibited an MDA level to the order of 8.12 ng/ml (Fig. 14). On the 
contrary, augmented MDA levels in 24 hr monocyte cultures supernatants from 
patients with SLE (n=3), TB (n=3) and SLE-TB (n=3) were found, which were of 
the order 18.22 ng/ml (2.24-folds; P<0.001), 17.34 ng/ml (2.12-folds; P<0.001) 
and 22.26 ng/ml (2.74-folds; P<0.001) respectively (Fig. 14). 
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7. NAC and EGCG-induced modulation of MDA levels In 24 hr culture 
filtrate of monocytes of patients with SLE, TB and SLE-TB 
To have further in-sight, an attempt was also made to probe the modulatory 
effect of NAC and EGCG on augmented levels of MDA in culture supernatants of 
the above monocyte cultures that were harvested after 24 hrs. As described 
above in Fig. 14, normal healthy control cultures exhibited 8.12 ng/ml of MDA, 
and augmented to the order of 18.22 ng/ml, 17.34 ng/ml and 22.26 ng/ml in 
cultures from patients with SLE (n=3), TB (n=3) and SLE-TB (n=3) respectively. 
On the contrary, modulation with 10 mM NAC showed down-regulation in MDA 
levels to 10.32 ng/ml. 9.34 ng/ml and 9.01 ng/ml in cultures from patients with 
SLE. TB and SLE-TB respectively (Fig. 15). Similarly, EGCG (5 ug/ml) exhibited 
down-regulation in MDA levels to 8.23 ng/ml. 7.89 ng/ml and 7.12 ng/ml in 
cultures from patients with SLE, TB and SLE-TB respectively (Fig. 16, P<0.001 
for all three groups of patients). 
(IV) IMMUNONOLICAL STUDY: 
1. Immuno-binding of dsDNA antigens by antibodies present in sera of 
patients with SLE by direct binding and inhibition-ELISA: 
The binding of naturally occurring SLE autoantibodies with a variety of antigens, 
ranging from native calf thymus purified DNA (free of proteins and single 
stranded regions) to mycobacterial protein antigens was probed by direct binding 
and inhibition ELISA. Prior to any study, SLE sera (n = 40) were screened for 
their activity. Only those SLE sera exhibiting a titer of greater than 1:6400 (n=20) 
against native DNA (Fig. 17) were selected for determining the reactivity against 
mycobacterial protein antigens. It is to be pointed out that apart from showing 
high magnitude specificity towards native DNA, the selected SLE sera having 
anti-DNA antibody also showed appreciable degree of reactivity towards a wide 
spectrum of antigens. Also, it's worth mentioning out here that prior to any ELISA 
experiments, it was ensured that the secreted mycobaterial proteins were free 
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from any contaminants of DNA due to possible leakage from ruptured bacilli, 
which in turn, may yield false positive test. Colorimetric estimations showed 
absence of any DNA contaminations in the culture filtrate having secreted 
proteins (data not shown). Thereafter, direct binding ELISA on micrctiter plates 
coated with intracellular and secreted mycobacterial protein antigens exhibited 
an anti-DNA antibody titer of greater that 1:12800 (Fig. 18, 19; P<0.001 for all). 
Normal human sera, which acted as corresponding controls failed to show any 
appreciable reactivity. Surprisingly, the binding curves showed augmented 
reactivity of SLE anti-DNA antibodies against mycobacterial protein antigens than 
against native dsDNA. 
Next, after observing high binding with SLE sera, an attempt was also made to 
check the binding with Protein-A-Sepharose purified SLE IgG. The binding 
curves by direct binding ELISA on plates coated with secreted mycobacterial 
protein antigens against SLE IgG (n=4) were of similar pattern observed with 
SLEsera(Fig. 20;P<0.001). 
After determining the reactivity of SLE anti-DNA antibodies by direct binding 
ELISA, an attempt was also made to determine the specificity of the above 
autoantibodies in SLE sera by employing competition-inhibition ELISA. A variety 
of inhibitors ranging from nucleic acids to mycobacterial proteins were employed 
in inhibition ELISA. As evident from Fig. 21, double stranded DNA showed a 
maximum inhibition in the anti-DNA antibody binding to the order of 73.11 
percent (P<0.001) at a maximum inhibitor concentration of 10 pg/ml. Here, fifty 
percent inhibition in the antibody activity was observed at 2.1 ug/ml. Similar 
maximum inhibition in antibody activity was observed with heat denatured single 
stranded DNA (71.33%; P<0.001), but fifty percent inhibition in antibody activity 
was recorded a much lower ssDNA inhibitor concentration (1.2 ug/ml). Next, no 
appreciable inhibition in antibody activity was observed v«/hen RNA was 
employed as an inhibitor (Fig. 22; P£05). 
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Thereafter, secreted mycobacterial protein antigens(s), were employed as 
inhibitors. As evident from Fig. 23, 82.13 percent inhibition in SLE IgG acti\/itles 
respectively were recorded at maxiinum inhibitor concentrations of 10 pg/ml 
(P<0.001). Fifty percent inhibition in SLE IgG activities was recorded at an 
inhibitor concentration of 0.01 pg/ml. Next, the above observations were further 
substantiated from results obtained by employing immunoaffinity purified (DNA-
polylysyl-sepharose 4B column) anti-DNA antibody (SLE IgG) in the binding 
studies (Fig. 24). It may be pointed out here that the lower the inhibitor 
concentration at which fifty percent inhibition is achieved, the greater the 
specificity of the concerned antibody towards the concerned antigen/inhibitor. 
Thus, judged on the basis of fifty percent inhibition, the binding curves indicate 
the presence of highly specific autoantibodi'^s in SLE sera for Mycobacterium 
tuberculosis H37RV secreted protein antigen (s). Thus, the above results show 
that the binding of SLE anti-DNA autoantibodies were of greater magnitude 
towards mycobacterial secreted protein antigens as compared to native DNA. 
Next, in sharp contrast to the above, when anti-TB antibodies (sera from TB 
patients, n=30) were employed on plates coated with dsDNA, then no binding 
was observed (Fig. 25) in direct binding ELISA. Since, DNA binding with TB sera 
was not observed in direct binding ELISA, thus, inhibition ELISA was not carried 
out. 
2. Immuno-binding of MTB SOkDa antigens by antibodies present in sera of 
patients with SLE and TB by inhibition-ELISA: 
All the TB sera's (n=30) undertaken in this study were subjected to specificity 
determination against respective antigens and inhibitors i. e. tuberculosis 85B 
antigen (30kDa) for TB sera and dsDNA for SLE patients respectively, by 
employing competition-inhibition ELISA. 
inhibition ELISA on plates coated with mycobacterium tuberculosis 85B antigen 
(30kDa) against sera of patients (n=30) with TB indicated interesting results 
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Nearly all the TB sera employed in this study exhibited a maximum of 84 percent 
inhibition (P<0.001) in anti-TB antibody activity at a maximum inhibitor (i.e. y^lTB 
30kDa) concentration of 10 pg/ml (Fig. 26). Fifty percent inhibition here was 
achieved at an inhibitor concentration of 0.1 |jg/ml, thereby indicating the high 
specificity of TB antibodies in TB sera against MTB 30kDa. 
Next, after selecting high specificity sera's of TB and SLE patients as described 
above, an attempt was made to evaluate the correlation, if any, between TB and 
autoimmune SLE. For this purpose, we investigated the (a) reactivity/specificity 
of anti-DNA antibodies found in SLE sera (n=20) against mycobacterial Ag85B 
(30 kDa) in comparison to dsDNA, (b) reactivity/specificity of anti-TB antibodies 
found in TB sera (n=20) against dsDNA in comparison mycobacterial Ag85B (30 
kDa), and (c) comparative reactivity of dsDNA versus MTB 30 kDa against sera 
from patients having both TB and SLE (n=20). 
As evident from Fig. 27, sera of patients with SLE (n=30) exhibited a maximum of 
87.7% (P<0.001) inhibition with dsDNA on microliter ELISA plates coated with 
dsDNA, where 50% inhibition in anti-DNA antibody activity was recorded at an 
inhibitor concentration of 0.08 ug/ml (Fig. 27). Interestingly, when MTB 30kDa 
was employed as an inhibitor on plates coated with dsDNA, then a magnitude of 
binding was observed with anti-DNA Abs found in SLE sera. A maximum of 
78.2% inhibition (P<0.001) in anti-DNA activity was recorded by 10 ug/ml of 
mycobacterial 30kDa antigen/inhibitor, where 50% inhibition was achieved at an 
inhibitor concentration of 0.09 pg/ml (Fig. 27). On the contrary, anti-TB antibodies 
found in TB sera (n=30) showed low magnitude recognition with dsDNA on plates 
coated with MTB 30kDa. Here only 29% (P>0.05) inhibition in anti-TB antibodies 
was recorded with dsDNA (Fig. 28), and that, 50% inhibition could not be 
achieved. However the same anti-TB antibodies on the same antigen (30 kDa) 
coated plates showed high magnitude antibody recognition (83%; P<0.001) when 
MTB 30kDa was employed as an inhibitor (Fig. 28). Thus, the results are 
indicative for an appreciable immunological correlation between SLE and TB. To 
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have further insight, inhibition-ELISA against dsDNA and MTB 30 kDa was 
carried out by using antibodies present in sera of patients having both SLE and 
TB. Here, a maximum of 95% and S3% (P<0.001) inhibition was observed with 
dsDNA and IVITB 30kDa inhibitors respectively on plates coated with MTB 30 
kDa antigen against Abs found in sera of patients having both the diseases i. e. 
SLE and TB (TB-SLE) (n=30) (Fig. 29). Fifty percent inhibition in both cases was 
recorded at very low inhibitor concentrations (0.07 [jg/ml for both). The data 
depicted in Fig 29 are again indicative for the close immunological relationship 
between SLE and TB. 
3. Immuno-recognition of antigens found in human monocytes of SLE and 
TB patients by anti-dsDNA Abs and anti-T'3 Abs found in patients with SLE 
andTB 
Next, we also carried out a number of inhibition-ELISA's to probe the binding 
effects by employing antigen / inhibitors obtained from cell lysates of human 
monocytes from TB and SLE patients. Figures 30 and 31 illustrates the binding of 
anti-TB antibodies and anti-DNA Abs found in sera of patients with TB (n=5) and 
SLE (n=5) respectively with protein lysates obtained from monocytes (0.5 x 
10^/well) from blood of respective TB and SLE patients that were cultured for 24 
hrs in 12-well tissue culture plates. 
Here, a maximum of 91.8% (P<0.001) and 95.9% (P<0.001) inhibitions in anti-TB 
and anti-dsDNA Ab activity respectively were recorded at a maximum inhibitor 
concentration of 10 ug/ml, where 50% inhibitions in the anti-TB Ab activity was 
achieved at a low inhibitor concentration of 0.08 ug/ml (Fig. 30), whereas that for 
anti-DNA from SLE sera was achieved at an inhibitor concentration of 0.07 ug/ml 
(Fig. 31). A further augmented inhibition (~ 97%; P<0.001) in anti-TB antibody 
activity was observed with sera of patients having both TN and SLE (n=5) (Fig. 
32) at a maximum inhibitor concentration of only 1 pg/ml, and that, 50% inhibition 
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in this case was recorded at a much low inhibitor concentration of 0.01 Mg/ml 
(Fig. 32). 
4. Reduced Glutathione-induced immuno-suppression studies 
In view of the role of reactive oxygen species (ROS) in both autoimmune SLE 
and tuberculosis (TB) being well documented, an attempt was made in the 
present study to neutralize/suppress the ROS induced effects in monocytes of 
patients with TB and SLE by employing reduced glutathione (r GSH), which is a 
known in vivo antioxidant. Thus, for this purpose, monocytes from blood of 
patients with SLE (n=5), TB (n=5) and SLE-TB (n=5) were isolated as described 
in methods and were adhered onto 12-well tissue culture plates and cultured with 
or without 10 nM of reduced glutathione for 24 hrs at 37 °C / 5%C02. Thereafter, 
treated/untreated monocytes were lysed in 1 ml/well of protein lysis buffer and 
were subsequently used as antigen / inhibitor in inhibition ELISA against 
antibodies in sera with SLE or TB or SLE-TB. 
As evident from Fig. 33, co-culturing of monocytes obtained from TB patients 
with 10 nM of reduced glutathione for 24 hrs resulted in the tremendous amount 
of down-regulation of recognition of anti-TB antibodies by cell lysates of the 
above cultured monocytes. Here, only a maximum of 32% (P>0.01) inhibition in 
anti-TB antibody activity was recorded at a maximum inhibitor concentration of 
20 pg/ml, and that, 50% inhibition could not be achieved here (Fig. 33). Thus, 
when compared to the data in Fig 30, reduced glutathione suppressed the anti-
TB antibody activity (Fig. 33) by around 58%. Similarly, in comparison to binding 
results depicted in Fig. 31, reduced glutathione down-regulated the anti-DNA 
antibody activity in monocytes of SLE patients by ~ 53% (P<0.01) (Fig. 34). On 
the other hand, reduced glutathione suppressed the anti-TB antibody activity in 
monocytes of patients with SLE-TB by ~ 36% (P<0.01) (Fig. 35) in comparison to 
untreated monocytes of TB-SLE patients whose data are depicted in Fig. 32). 
Thus, the results indicate the high magnitude suppression in respective antibody 
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binding (i. e. abb in sera of patients with SLE or TB or SLE-TB) to corresponding 
antigens by reduced glutathione. 
5. Binding studies with anti-TNF-a antibody 
in view of the fact that ROS activates the production of autocrine proinflammatory 
cytokine, namely TNF-a, which in turn, is involved in the pathogenesis of TB and 
SLE, thus an attempt was made in the present study to evaluate the binding of 
anti-TNF-a antibody with various antigens prepared and used in the above-
mentioned modulatory studies. Figures 36-38 demonstrates the binding of anti-
TNF-a antibody with protein lysates of monocytes from patients with TB (n=5), 
SLE (n=5) and TB-SLE (n=5). 
A maximum of 68.9% (P<0.001) inhibition in anti- TNF-a antibody activity was 
recorded at a maximum inhibitor (i. e. lysates of monocytes from TB patients) 
concentration of 1 pg/ml, where 50 % inhibition was achieved at an inhibitor 
concentration of 0.08 pg/ml (P<0.001) (Fig. 36). On the other hand, a maximum 
of 76.5% (P<0.001) inhibition in anti- TNF-a antibody activity was recorded at a 
maximum inhibitor (i. e. lysates of monocytes from SLE patients) concentration of 
10 |jg/fTil, where 50 % inhibition was achieved at an inhibitor concentration of 
0.09 pg/ml (P<0.001) (Fig. 37). It is noteworthy to observe that a maximum of 
80.09 % (P<0.001) inhibition in anti- TNF-a antibody activity was achieved at a 
maximum inhibitor (i. e. lysates of monocytes from SLE-TB patients) 
concentration of only 0.1 \ig/m\, where 50 % inhibition was recorded at an 
inhibitor concentration of 0.05 pg/ml (P<0.001) (Fig. 38). 
Co-culturing of monocytes obtained from patients having TB (n=5), SLE (n=5) 
and TB-SLE (n-5) with reduced glutathione (10 nM) for 24 hrs resulted in the 
suppression of recognition of anti-TNF- a Ab. Here, only a maximum of 17.26%, 
28.03% and 32.01% (P>0.01for all) inhibition in anti- TNF-a antibody activity was 
recorded as is evident from Figs. 39-41, respectively. 
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6. Measurement of secreted TNF- a in 24 hr culture supernatants of 
monocytes treated with reduced glutathione. 
Level of secreted TNF- a in culture supernatants was found to be greatest in 
cultures of monocytes from patients with TB-SLE, followed by cultures of 
monocytes of SLE and TB patients respectively (P<0.001 for all) (Fig. 42). The 
order of reduced glutathione-induced suppression in secreted TNF- a in 
monocyte culture supernatants was TB > SLE > TB-SLE (P<0.001) (Fig. 42). It is 
noteworthy to observe that secreted TNF-alpha was highest in culture 
supernatants of patients belonging to category III (Age: 51 yrs to 65 yrs), followed 
by category II (Age: 36 yrs to 50 yrs) and category I (Age: 20 yrs to 35 yrs) 
respectively (Fig. 42). 
7. Binding of anti-DNA antibodies against dsDNA antigen/inhibitor isolated 
from monocytes of SLE patients that were co-cultured for 24 hr with NAC, 
EGCG, SN50orSN50M. 
DNA was isolated by Qiagen Kit from untreated / treated monocytes from 
patients with SLE (n=5), and were subsequently employed as coating antigen / 
inhibitor in inhibition-ELISA. As evident from Fig. 43, the specificity of anti-DNA 
antibodies against dsDNA isolated from SLE monocytes that were co-cultured for 
24 hr with 10 mM NAC was found to decrease markedly to 41.2 percent 
(P<0.001) when compared to control untreated monocytes (73.45 percent) (Fig. 
43). Here, fifty percent inhibition could be achieved with any of the inhibitor 
concentrations employed. Next, dsDNA isolated from SLE monocytes (n=5) that 
were co-cultured for 24 hr with 5 ug/ml EGCG was employed as coating antigen / 
inhibitor, then a maximum of only 32.45 percent inhibition (P<0.001) was 
observed (Fig. 44). Again, here fifty percent inhibition could not be achieved. The 
results thus indicate the positive involvement of reactive oxygen species (ROS) 
in SLE. which was appreciably neutralized / inhibited by NAC and EGCG. 
Thereafter, for reasons ds described in modulation studies earlier, an attempt 
was also made to probe the immuno-binding of anti-DNA antibodies against 
dsDNA isolated from SLE monocytes (n=5) treated wim SN50 and SN50M. As 
evident from Fig. 45, anti-DNA antibodies exhibited a non-significant binding with 
SN50 treated SLE monocytes (39.22 percent). On the contrary, treatment with 
control peptide SN50M exhibited high binding as is evident by 69.44 percent 
inhibition in anti-dsDNA antibody activity (Fig. 45, P<0.001). Thus, the activation 
of NF-kB and in turn, its involvement in SLE is substantiated by the above 
immuno-binding data. 
8. Anti-DNA antibody binding against dsDNA antigen/inhibitor isolated from 
monocytes of tuberculosis (IB) patients that were co-cu'tured for 24 hr 
with NAC, EGCG, SN50 or SN50M. 
As mentioned above, DNA was isolated from untreated / treated monocytes from 
patients with TB (n=5), and were subsequently employed as coating antigen / 
inhibitor in inhibition-ELISA. As evident from Fig. 46, the specificity of anti-DNA 
antibodies against dsDNA isolated from TB monocytes that were co-cultured for 
24 hr with 10 mM NAC was found to decrease markedly to 46.56 percent 
(P<0.001) when compared to control untreated monocytes (79.33 percent) (Fig. 
46). Fifty percent inhibition could not be achieved with any of the inhibitor 
concentrations employed. Similarly, dsDNA isolated from monocytes of TB 
patients (n=5) that were co-cultured for 24 hr with 5 pg/ml EGCG, and in turn, 
were employed as coating antigen / inhibitor in ELISA. The results show a 
maximum of only 29.45 percent inhibition in comparison to cells devoid of EGCG 
(maximum inhibition to the order of 79.33%) (P<0.001) (Fig. 47). Again, here fifty 
percent inhibition could not be achieved. The results thus indicate the positive 
involvement of reactive oxygen species (ROS) in TB, which was appreciably 
neutralized / inhibited by NAC and EGCG. The results also indicate involvement 
of mycobacterial antigen(s) in SLE as is evident from high binding of anti-DNA 
antibodies with mycobacterial DNA. 
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Thereafter, as described in modulation studies earlier, an attempt was also made 
to probe the immuno-binding of anti-DNA antibodies (n=5) against dsDNA 
isolated from TB monocytes (n=5) treated with SN50 and SN50M. As evident 
from Fig. 48, anti-DNA antibodies exhibited a maximum inhibition of only 35.39 
percent with SN50 treated TB monocytes (P<0.005). On the contrary, DNA 
isolated from monocytes treated with control peptide SN50M exhibited high 
binding as is evident by 71.42 percent inhibition in anti-dsDNA antibody activity 
(Fig. 48, P<0.001). Thus, the activation of NF-kB and in turn, its involvement in 
TB is substantiated by the above immuno-binding data. This is in accordance 
with earlier reports from our laboratory at the molecular level (Hasan et al., 
2006). 
9. Cross reactivity of anti-TB antibodies against dsDNA antigen/inhibitor 
isolated from monocytes of SLE patients that were co-cultured respectively 
for 24 hr with NAC, EGCG, SN50 or SN50M. 
Next, after ascertaining the immuno-binding of anti-DNA antibodies from SLE 
patients, an attempt was made to evaluate the specificity / binding of anti-TB 
antibodies found in patients with TB against DNA isolated from untreated/treated 
monocytes of patients with (i) SLE, (ii) TB and (iii) SLE-TB. 
Inhibition-ELISA results show no or negligible binding of anti-TB antibodies found 
in sera of patients with TB (n=5) against dsDNA isolated from untreated / treated 
monocytes of SLE patients (n=5) that were cultured for 24 hr. As evident from the 
binding curves, a maximum inhibition in anti-TB antibody activity to the order of 
only 10.23 percent was observed (Fig. 49). Similarly, negligible inhibitions in anti-
TB antibody activity of the order of 8.34 percent, 7.12 percent, 9.42 percent, 8.19 
percent and 13.44 percent was observed with ds DNA isolated from control 
untreated. 10 mM NAC treated, 5 pg/ml EGCG treated, 100 pg/ml SN50 treated 
and 100 pg/ml SN50M treated monocytes respectively from SLE patients (Fig. 
50). 
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Fig. 1. Expression of human house keeping gene R18 rRNA in 
monocytes of patients with SLE (n=3; P<0.001), TB (n=3; P<0.001) 
and SLE-TB (n=3; P<0.001). Monocytes from normal healthy 
individuals served as controls (n=3). Data represents mean + SEM of 
3 experiments. 
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Fig. 2. Expression of human TNF-a mRNA in monocytes of patients 
with SLE (n=8; P<0.001), TB (n=8; P<0.001) and SLE-TB (n=8; 
P<0.001). iVIonocytes from normal healthy individuals served as 
controls (n=3). Data represents mean + SEM of 8 experiments. 
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Fig. 3. Expression of secreted TNF-a protein in 24 hr culture 
supernatants of monocytes of patients with SLE (n=8; P<0.001), TB 
(n=8; P<0.001) and SLE-TB (n=8; P<0.001). Monocytes from normal 
healthy individuals served as controls (n=8). The concentration of 
secreted TNF- a was in pg/ml. Data represents mean + SEM of 8 
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Fig. 5. Expression of secreted IFN-y protein in 24 hr culture 
supernatants of monocytes of patients witii SLE (n=8; P<0.001), TB 
(n=8; P<0.001) and SLE-TB (n=8; P<0.001). Monocytes from normal 
healthy individuals served as controls (n=8). The concentration of 
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Fig. 6. Determination of glutathione peroxidase (GPx) activity in 
monocytes of patients witii SLE (n=8; P<0.001), TB (n=8; P<0.001) 
and SLE-TB (n=8; P<0.001). IVIonocytes from normal healthy 
individuals served as controls (n=8). The unit of GPx activity was 
determined as U/mg protein. Data represents mean + SEM of 8 
experiments. 
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Fig. 7. Dose response effect of NAC (0-10 mM) on the expression of 
secreted TNF-a in 24 hr culture filtrates of monocytes of patients with 
SLE (black bars; n=3; P<0.001), TB (square bars; n=3; P<0.001) and 
SLE-TB (ladder bars; n=3; P<0.001). Monocytes from normal healthy 
individuals served as controls (empty bars; n=3). Data represents 
mean + SEM of 8 experiments. 
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Fig 8: MTT cell viability assay for dose-response (0 - 25 ug/ml) effect 
of ECGC on 24 hr monocytes cultures of patients with SLE (black 
bars; n=3), TB (square bars; n=3), SLE-TB (ladder type bars; n=3) 
and normal healthy controls (empty bars; n=3). After 24 hrs of culture, 
the cells were harvested and processes as described in methods. 
Data represents the analysis of three independent experiments in 
duplicates, which are expressed as mean viable cells (+S. E.) 
percentage of controls. (P<0.001). 
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Fig. 9. Expression of human house keeping gene R18 r18 mRNA in 
24 hr monocyte cultures treated with 5 |jg/ml of EGCG. The 
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Fig. 10. Dose response effect of EGCG (0-25 pg/ml) on the 
expression of secreted TNF-a protein in 24 hr culture supernatants of 
monocytes of patients with SLE (black bars; n=5; P<0.001), TB 
(square bars; n=5; P<0.001) and SLE-TB (ladder bars; n=5; 
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Fig. 11. Effect of SN50 (black bars; 100 pg/mlSN50M) and control 
peptide SN50M (square bars; 100 pg/ml) on the expression of 
secreted TNF-a protein in 24 hr culture supernatants of monocytes of 
patients with SLE (n=5; P<0.001), TB (n=5; P<0.001), SLE-TB (n=5; 
P<0.001) and normal healthy individuals (n=5). Untreated cultures 
served as controls (empty bars). The concentration of secreted TNF-
a was in pg/ml. Data represents mean + SEM of 5 experiments. 
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Fig. 12. NAC (10 mM)-induced modulation of glutathione peroxidase 
(GPx) activity (U/mg protein) in 24 hr monocytes cultures of patients 
with SLE (black bars; n=8; P<0.001), TB (square bars; n=8; P<0.001) 
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Fig. 13. EGCG (5 |jg/ml)-incluced modulation of glutathione 
peroxidase (GPx) activity (U/mg protein) in 24 hr monocytes cultures 
of patients with SLE (black bars; n=8; P<0.001), TB (square bars; 
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from normal healthy individuals served as controls (empty bars; n=8). 
Data represents mean + SEM of 8 experiments. 
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Fig. 14. Expression MDA in 24 hr culture supernatants of monocytes 
of patients with SLE (n=3; P<0.001), TB (n=3; P<0.001) and SLE-TB 
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Fig. 15. Modulation of the expression MDA levels by 10 mM NAC in 
24 hr culture supernatants of monocytes of patients with SLE (n=3; 
P<0.001), TB (n=3; P<0.001) and SLE-TB (n=3; P<0.001). 
Monocytes from normal healthy individuals served as controls (n=3; 
P<0.001). The concentration of MDA measured was in pg/ml. Data 
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Fig. 16. Modulation of the expression MDA levels by 5 ug/ml EGCG 
in 24 hr culture supernatants of monocytes of patients with SLE (n=3; 
P<0.001), TB (n=3; P<0.001) and SLE-TB (n=3; P<0.001). 
Monocytes from normal healthy individuals served as controls (n=3). 
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Fig. 17. Direct binding ELISA on microtitre ELISA plates that were 
coated with purified calf thymus dsDNA (100 ul/weil from 250 ng/ml 
stock) against anti-DNA antibodies {-A- ; SLE sera; n=20; P<0.001). 
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Fig. 18. Direct binding ELISA on microtitre ELISA plates that were 
coated with Mycobacterial total sonic extract (100 ul/well from 20 
ug/ml stock) against anti-DNA antibodies (-A-; SLE sera; n=20; 
P<0.001). Normal human sera served as controls (-A-; NHS) Data 
represents mean + SEM of number of experiments. 
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Fig. 19. Direct binding ELISA on microtitre ELISA plates that were 
coated with Mycobacterial total culture filtrate (MTCF) (100 pi/well 
from 20 ug/ml stock) against anti-DNA antibodies (-A- ; SLE sera; 
n=20; P<0.001). Normal human sera served as controls (-A-;NHS; 
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Fig. 20. Direct binding ELISA on microtitre ELISA plates that were 
coated with Mycobacterial total culture filtrate (MTCF) (100 jjl/well 
from 20 ug/ml stock) against Sepharose 4B purified SLE IgG i. e. 
purified anti-DNA antibodies (-A-; IgG from SLE sera; n=4; P<0.001). 
Normal human sera served as controls (-A-; IgG from NHS; n=4). 
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Fig. 21. Inhibition ELISA on microtitre ELISA plates that were coated 
with dsDNA (-f) (100 ul/well from 2.5 ng/ml stock) and ssDNA (-•-) 
(100 ul/well from 2.5 ng/ml stock) against Sepharose 4B purified SLE 
IgG i. e. purified anti-DNA antibodies (n=4; P<0.001). The inhibitors 
were dsDNA and ssDNA. The immune complex prepared was used 
in place of antibody as described in methods. Fifty percent inhibition 
in anti-DNA antibody activity (IC50) for dsDNA and ssDNA was 
computed out to be 2.2 pg/ml and 1.2 ug/ml respectively. Data 
represents mean + SEM of 4 experiments. 
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Fig. 22. Inhibition ELISA for RNA on microtitre ELISA plates that 
were coated with dsDNA (-•-) (100 ul/well from 2.5 ng/ml stock) 
against Sepharose 4B purified SLE IgG i. e. purified anti-DNA 
antibodies (n=4; P<0.001). The inhibitor used to prepare immune 
complex was RNA. The immune complex was used in place of 
antibody as described in methods. Fifty percent inhibition in antibody 
activity (IC50) could not be achieved. Data represents mean + SEM of 
4 experiments. 
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Fig. 23. Inhibition ELISA for IVITCF on microtitre ELISA plates that 
were coated with dsDNA (100 |j|/well from 2.5 ng/ml stock) against 
Sepharose 4B purified SLE IgG i. e. purified anti-DNA antibodies 
(n=4; P<0.001). The inhibitor was MTCF. The immune complex 
prepared with varying doses of MTCF was used in place of antibody 
as described in methods. Fifty percent inhibition in anti-DNA antibody 
activity (IC50) was computed out to be 0.01 ug/ml. (MTCF= 
Mycobacterial total culture filtrate i. e. secretory proteins). Data 
represents mean + SEM of 4 experiments. 
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Fig. 24. Inhibition ELISA for IVITCF on microtitre ELISA plates that 
was coated with dsDNA (100 ul/well from 2.5 ng/ml stock) against 
immunoaffinity purified anti-DNA antibodies (on DNA-polylysyl-
sepharose 4B column) i. e. immunoaffinty purified SLE IgG (n=4; 
P<0.001). The inhibitor was dsDNA (-D-) and MTCF (-•-). The 
immune complex prepared with varying doses of dsDNA or MTCF, 
and was used in place of antibody as described in methods. Fifty 
percent inhibition in anti-DNA antibody activity (IC50) was computed 
out to be 0.01 ug/ml for both dsDNA and MTCF. (MTCF= 
* 
Mycobacterial total culture filtrate i. e. secretory proteins). Data 
represents mean + SEM of 4 experiments. 
97 
0.5 
I 0.4 
TO 
0) 1 
I 0.2 I 
o 
0.1 
.^^ .^^ .^^ ^^ ^ ^^ ^ n^^ ^S? «SJ^  A^ ..'V' ..t^ .A" A^" .'b^" .^^" .'V^ ^ \ - K' \ ' ' ,^ A 
Serial TB Sera Dilution 
-» -NHS •TB sera 
Fig. 25. Direct binding ELISA on microtitre ELISA plates that were 
coated with dsDNA (100 |jl/well from 2.5 ng/ml stock) against TB 
antibodies (TB sera) (-n-). Normal human sera served as controls (-•-
NHS). No binding was observed, as the titer was <1:100. Data 
represents mean + SEM of 8 experiments. 
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Fig. 26. Inhibition ELISA against antibodies in sera of patients with TB 
(n=30) on plates coated with 30 kDa Ag85B isolated from mid-
logarithmic phase cultures of Mycobacterium tuberculosis H37RV. The 
inhibitor used here was varying concentrations of 30 kDa Ag85B. 
The concentrations were 0.01, 0.1, 1.0, 10 and 20 pg/ml. Data are 
mean ±SD. 
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Fig. 27. Comparative Inhibition ELISA against autoantibodies in 
Patients with SLE (n=30) on plates coated with native dsDNA (non 
mycobacterial), where the inhibitors used were varying 
concentrations of native dsDNA versus mycobacterial 30 kDa 
Ag85B.The concentrations for both the inhibitors were 0.01, 0.1, 1.0, 
10 and 20 |jg/ml. dsDNA (-•-) and mycobacteria! SOkDa Ag85B (-A 
). Data are mean ±SD. 
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Fig. 28. Comparative Inhibition ELISA against antibodies in patients 
with TB (n=30) on plates coated with mycobacterial 30 kDa Ag85B, 
where the inhibitors used were varying concentrations of 
mycobacterial 30 kDa Ag85B versus non-mycobacterial native 
dsDNA. The concentrations for both the inhibitors were 0.01, 0.1, 1.0, 
10 and 20 pg/ml. Mycobacterial 30 KDa (Black bars) and non-
mycobacterial native dsDNA (shaded bars). Data are mean ±SD. 
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Fig. 29. Comparative Inhibition ELISA against antibodies in patients 
with TB-SLE (n=30) on plates coated with mycobacterial 30 kDa 
Ag85B, where the inhibitors used were varying concentrations of 
mycobacterial 30 kDa Ag85B versus non-mycobacterial native 
dsDNA. The concentrations for both the inhibitors were 0.01, 0.1, 1.0, 
10 and 20 ng/ml. Mycobacterial 30 kDa Ag85B (Black bars) and non 
mycobacterial native dsDNA (white bars). Data are mean ±SD. 
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Fig. 30. Inhibition ELISA against antibodies in sera of patients witli 
TB (n=5) on plates coated with total protein lysates obtained from 
human monocytes isolated from blood of TB patients where the 
inhibitor used were varying concentrations of the above mentioned 
total protein lysates obtained from monocytes of TB patients. The 
inhibitor concentrations were 0.01, 0.1, 1.0, 10 and 20 pg/ml. Data 
are mean ±SD. 
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Fig. 31. Inhibition ELISA against antibodies in sera of 
patients with SLE (n=5) on plates coated with non-
mycobacterial native dsDNA and the inhibitors used were 
lysates obtained from monocytes isolated from blood of SLE 
patients where the varying inhibitor concentrations were 
0.01, 0.1, 1.0, 10 and 20 |jg/ml. Data are mean ±SD. 
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Fig. 32. Inhibition ELISA against antibodies in sera of patients with 
TB-SLE (n=5) on plates coated with non-mycobacterial native dsDNA 
and the inhibitors used were lysates obtained from monocytes 
isolated from blood of SLE patients where the varying inhibitor 
concentrations were 0.01, 0.1, 1.0, 10 and 20 pg/ml. Data represents 
mean + SEM of 5 experiments. 
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Fig. 33. Modulation of TB monocytes with reduced glutathione: 
inhibition ELISA against antibodies in sera of patients with TB (n=5) 
on plates coated with total protein lysates obtained from TB patient 
monocytes that were co-cultured for 24 hrs with 10 nM of reduced 
glutathione where the varying inhibitor concentrations used of the 
above mentioned total protein lysates were 0.01, 0.1, 1.0, 10 and 20 
jjg/ml. Data represents mean + SEM of 5 experiments. 
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Fig. 34. Modulation of SLE monocytes with reduced glutathione: 
Inhibition ELISA against antibodies in sera of patients with SLE (n=5) 
on plates coated with total protein lysates obtained from SLE patient 
monocytes that were co-cultured for 24 hrs with 10 nM of reduced 
glutathione where the varying inhibitor concentrations used of the 
above mentioned total protein lysates were 0.01, 0.1, 1.0, 10 and 20 
|jg/ml. Data are mean ±SD. Data represents mean + SEM of 5 
experiments. 
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Fig. 35. Modulation of TB-SLE monocytes with reduced glutathione: 
Inhibition ELISA against antibodies in sera of patients with TB-SLE 
(n=5) on plates coated with total protein lysates obtained from TB-
SLE patient monocytes that were co-cultured for 24 hrs with 10 nM of 
reduced glutathione where the varying inhibitor concentrations used 
of the above mentioned total protein lysates were 0.01, 0.1, 1.0, 10 
and 20 |jg/ml. Data represents mean + SEM of 5 experiments. 
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Fig. 36. Anti-TNF-a antibody Activity: Inhibition ELISA against 
monoclonal ant'-TNF-a antibody on plates coated with total protein 
lysates obtained from human monocytes isolated from blood of TB 
patients (n=5) where the inhibitor used were varying concentrations 
of the above mentioned total protein lysates obtained from monocytes 
of TB patients. The inhibitor concentrations were 0.01, 0.1, 1.0, 10 
and 20 |jg/ml. Data represents mean + SEM of 5 experiments. 
109 
Si 
< 
a t 
u. 
z 
ll 
c 
c S 
— > 
O U 
s < 
IE 
c 
0) 
Q. 
100 
80 
60 
40 
20 I 
0.01 
Inhibitor Concentration (pg/ml) 
Fig. 37. Anti-TNF-a antibody activity: iniiibition ELiSA against 
monoclonal anti-TNF-a antibody on plates coated with total protein 
lysates obtained from monocytes isolated trom blood of SLE patients 
(n=5) where the inhibitor used were varying concentrations of the 
above mentioned total protein lysates obtained from monocytes of 
SLE patients. The inhibitor concentrations were 0.01, 0.1, 1.0, 10 and 
20 |jg/ml. Data represents mean + SEM of 5 experiments. 
100 
Si 
< 
s 
UL 
z 
c 
0) 
u 
Q. 
80 
« ^ 60 
C £ 
'- > 
o o 
S < 
40 
20 
0.01 0 1 1.0 10 
Inhibitor Concentration (pg/ml) 
20 
Fig. 38. Anti-TNF-a antibody activity: Inhibition ELISA against 
monoclonal anti-TNF-a antibody on plates coated with total protein 
lysates obtained from morocytes isolated from blood of TB-SLE 
patients (n=5) where the inhibitor used were varying concentrations 
of the above mentioned total protein lysates obtained from monocytes 
of TB-SLE patients. The inhibitor concentrations were 0.01, 0.1, 1.0, 
10 and 20 pg/ml. Data repre-^nts mean + SEM of 5 experiments. 
< 
o 
u. 
z 
100 
80 
< >, 60 
— > 
O O 
•J5 < 
ja 
!E 
c 
40 
c 
u 
o 
Q. 
20 
0 iA t i 0.0 0.1 1 0 10 20 
Inhibitor Concentration (Mg/nil) 
Fig. 39. Modulation of TB monocytes with reduced glutathione versus 
Anti-TNF-a antibody Activity: Inhibition ELISA against antibodies in 
sera of patients with TB (n=5) on plates coated with total protein 
lysates obtained from TB patient monocytes that were co-cultured for 
24 hrs with 10 nM of reduced glutathione where the varying inhibitor 
concentrations used of the above mentioned total protein lysates 
were 0.01, 0.1, 1.0, 10 and 20 pg/ml. Data represents mean + SEM 
of 5 experiments. 
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Fig. 40. Modulation of SLE monocytes with reduced giutatiiione 
versus Anti-TNF-a antibody Activity: Inhibition ELISA against 
antibodies in sera of patients with SLE (n=5) on plates coated with 
total protein lysates obtained from SLE patient monocytes that were 
co-cultured for 24 hrs with 10 nM of reduced glutathione where the 
varying inhibitor concentrations used of the above mentioned total 
protein lysates were 0.01, 0.1, 1.0, 10 and 20 |jg/ml. Data represents 
mean + SEM of 5 experiments. 
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Fig. 41. Modulation of TB-SLE monocytes with reduced glutathione 
versus Anti-TNF-a antibody Activity: Inhibition ELISA against 
antibodies in sera of patients with TB-SLE (n=5) on plates coated 
with total Protein lysates obtained from TB-SLE patient monocytes 
that were co-cultured for 24 hrs with 10 nM of reduced glutathione 
where the varying inhibitor concentrations used of the above 
mentioned total protein lysates were 0.01, 0.1, 1.0, 10 and 20 [ig/ml. 
Data represents mean + SEM of Sexperiments. 
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Fig. 42. Expression of secreted pro-inflammatory cytokine TNF-a in 
supernatants of monocytes that were cultured for 24 hrs with and 
without 10 nM of reduced glutathione. The different monocytes 
cultured were obtained from blood of patients having TB (n=5), SLE 
(n=5) and TB-SLE (n=5). Also in each group, three categories were 
undertaken in this study. They were: Category I: Patients in the age 
group of 20 yrs to 35 yrs (black bars), Category II: patients in the age 
group of 36 yrs to 50 yrs (white bars) and Category III: patients in the 
age group of 51 yrs to 65 yrs (shaded bars). Data represents mean + 
SEM of 5 experiments. 
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Fig. 43. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) on plates coated with dsDNA obtained from 
SLE patient monocytes (n=5) that were co-cultured for 24 hrs with 
without (-•-) or with 10 mM of NAC (-n-), where the varying inhibitor 
concentrations used were 0, 0.01, 0.1, 5 and 10 |jg/ml. Data 
represents mean + SEM of 5 experiments. P<0.001 for all. 
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Fig. 44. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) ori plates coated with dsDNA obtained from 
SLE patient monocytes (n=5) that were co-cultured for 24 hrs with 
without (-•-) or with 5 ug/ml of EGGG, (-a-), where the varying 
inhibitor concentrations used were 0, 0.01, 0.1, 5 and 10 |jg/ml. Data 
represents mean + SEM of 5 experiments. P<0.001 for all. 
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Fig. 45. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) on plates coated with dsDNA obtained from 
SLE patient monocytes (n=5) that were co-cultured for 24 hrs with 
without (-•-) or with 100 ug/ml SN50 (-A-) or 100 ug/ml SN50M (-n-), 
where the varying inhibitor concentrations used were 0, 0.01, 0.1, 5 
and 10 pg/ml. Data represents mean + SEM of 5 experiments. 
P<0.001 for all. 
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Fig. 46. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) on plates coated with dsDNA obtained from 
TB patient monocytes (n=5) that were co-cultured for 24 hrs with 
without (-•-) or with 10 mM of NAC (-a-), where the varying inhibitor 
concentrations used were 0, 0.01, 0.1, 5 and 10 pg/ml. Data 
represents mean + SEM of 8 experiments. P<0.001 for all. 
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Fig. 47. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) on plates coated with dsDNA obtained from 
TB patient monocytes (n=5) that were co-cultured for 24 hrs with 
without (-•-) or with 5 ug/ml EGCG (-n-), where the varying inhibitor 
concentrations used were 0, 0.01, 0.1, 5 and 10 pg/mi. Data 
represents mean + SEM of 5 experiments. P<0.001 for all. 
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Fig. 48. Inhibition ELISA against anti-DNA antibodies in sera of 
patients with SLE (n=5) on plates coated with dsDNA obtained from 
TB patient monocytes that were co-cultured for 24 hrs with without (-
•-) or with 100 ug/ml SN50M (-n-) or 100 ug/ml SN50 (-A-), where 
the varying inhibitor concentrations used were 0, 0.01, 0.1, 5 and 10 
pg/ml. Data represents mean + SEM of 5 experiments. P<0.001 for 
all. 
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Fig. 49. Inhibition ELISA against anti-TB antibodies in sera of patients 
with TB (n=5) on plates coated with dsDNA obtained from untreated 
SLE patient monocytes (n=5) that were cultured for 24 hrs, where the 
varying inhibitor concentrations used were 0, 0.01, 0.1, 5 and 10 
pg/ml. Data represents mean + SEM of 5 experiments. P<0.05 for all. 
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Fig. 50. Inhibition ELISA against anti-TB antibodies in sera of patients 
with TB (n=5) on plates coated with dsDNA obtained from SLE 
patient monocytes (n=5) that were co-cultured for 24 hrs with either 
10 mM NAC (empty bars), 5 |jg/ml EGCG (black bars), 100 [ig/rc\\ 
SN50 (square bars) and 100 pg/ml SN50M (ladder bars). The varying 
inhibitor (above respective dsDNA from treated cells) concentrations 
used were 0, 0.01, 0.1, 5 and 10 |jg/nril. Data represents mean + SEM 
of 5 experiments. P<0.05 for all. 
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DISCUSSION 
The immune system has tremendous discrimination potential of self and non-self. 
However, this enormous recognition potential includes possible interaction with 
self components, some of which may appear to be essential for the regulation of 
the immune functions (Alam et al., 1992) whereas others can be pathogenic, 
particularly if expressed at high level, leading to autoimmune diseases. 
Systemic Lupus Erythematosus (SLE) is a chronic, usually life-long, potentially 
fatal prototype autoimmune disease characterized by unpredictable 
exacerbations and remissions with protean clinical manifestations. In SLE there 
is a predilection for clinical involvement of the joints, skin, kidney, brain, serosa, 
lung, heart and gastroi. itestinal tract. SLE is a complex disorder affecting a 
predominately young population and shares similarities with HIV infection as 
regards the propensity for multiple organ involvement, potentially life-threatening 
episodes, and need for sophisticated monitoring. The clinical features of SLE are 
protean and may mimic infectious mononucleosis, lymphoma, or other systemic 
disease. The origin of autoantibody production in SLE is unclear but a role has 
been suggested for an antigen driven process, spontaneous B-cell hyper-
responslveness, or impaired immune regulation. Thus, the etiology of SLE 
remains unknown and warrants in-depth investigation for the management of the 
disease. Evidences exist for the involvement of mycobacterial protein antigens in 
the pathogenesis of autoimmune diseases (Tasneem et al., 2001). Despite 
current treatment regimens, tuberculosis continues to confound attempts at 
control, fuelling an urgent need for developing novel therapeutic strategies. 
Although attenuation of the biological activity of TNF-a has lately become an 
important therapeutic intervention in the management of a wide variety of chronic 
inflammatory diseases (Shanahan and St Clair, 2002), a growing body of clinical 
evidence indicates that neutralization of TNF-a is associated with an increased 
risk of opportunistic infections, including mycobacterial diseases (Dinarello, 
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2003), and autoimmune disorders. In view of this, modulation of TNF-a release is 
being proposed as the basis for novel therapeutic approaches (Warwick-Davies 
et a!., 2001). Focus has now shifted to development of compounds from natural 
sources that have anti-inflammatory and antimycobacterial activity. By boosting 
host immunologic responsiveness, these compounds may be particularly useful 
in the treatment of autoimmune disorders as well as drug-resistant tuberculosis. 
Our study involves the incorporation of such a compound, namely EGCG - a 
green tea polyphenol, as the natural herbal component for SLE and SLE-TB 
management. 
Reports indicate TNF-a exerting its effects through its receptors namely TNFR-I 
and TNFR-II is a central mediator of inflammation (Islam et al., 2004), immunity 
and autoimmunity and that; it plays a crucial role in host defense. Inhibition of 
TNF-a clearly predisposes to certain infections, such as granulomatous 
infections like TB. Inhibition of TNF-a may also play a role in autoimmunity 
(Malemud et al., 2003; Islam et al., 2002) although the pathophysiologic 
mechanisms are uncertain. Furthermore, cases of TB have been reported in 
patients treated with TNF-a antagonists. The risk for TB in RA/SLE patients is 
associated with multiple other factors including age, country of origin or current 
residence, exposure history to persons with TB, concomitant therapy with other 
immunomodulators including corticosteroids, and disease activity. TNF-a 
antagonists have been associated with an increase in the percentage of RA 
patients with positive serologies (ANA and anti-ds-DNA) and lupus-like 
syndromes. 
Cellular signalling by TNF-a is mediated mainly through activation of NF-KB 
(Baeuerle and Baltimore, 1996). In turn, activation of NF-KB and other pathways 
sustain TNF-a activity (Ropert et al., 2001). During characterization studies in 
order to assess the role of NF-KB in the expression of TNF-a in SLE, TB and 
SLE-TB monocytes, we employed SN50, an inhibitor of NF-KB. From our results, 
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it was apparent that the induction of TNF-a expression was mediated through 
activation of NF-KB, because TNF- a was suppressed when SN50 was present in 
cultures. The inactive analogue of SN50 (i. e. SN50M) did not have any effect. 
Thus, as previously reported in macrophages (Islam et al., 2004), this study also 
shows that cellular activation Is associated with augmentation of expression of 
both TNF-a in monocytes of patients with SLE, TB and SLE-TB. 
Putative and effective host defense mechanisms by innate immune cells to M. 
tuberculosis within the phagolysosomes of activated macrophages include the 
production of reactive oxygen (ROI) and reactive nitrogen intermediates (RNI). 
Phagocytosis of microbes as well as cellular activation activates ROIs (Takao et 
al., 199S), and H2O2, a product of the ROI pathway, activates the expression of 
iNOS and production of NO (Han et al., 2001). Both ROI and RNI are 
downstream mediators of macrophage-activating cytokines and are thought to be 
microbicidal. Activation of iNOS and production of NO may be important in the 
final containment of M. tuberculosis by macrophages (MacMicking et al., 1997). 
However, M. tuberculosis has evolved resistance mechanisms against both, ROI 
(Hillas et al., 2000) and RNI (St John et al., 2001). 
Cell viability and potential cytotoxicity of EGCG, if any, on monocytes obtained 
from patients with SLE, TB and SLE-TB were determined for the concentrations 
(0-25 Mg/ml) employed in this study using trypan blue and MTT assays, where 
viability of ~98-99% was observed. Interestingly, no effect of EGCG was 
observed on human housekeeping genes like R18 rRNA, thereby demonstrating 
that the effect of EGCG was not mediated by cellular death, but rather by specific 
inhibition of expression as well as secretion of TNF-a. 
To the best of our understanding, in our characterization studies, we show for the 
first time that EGCG exerts potent anti-inflammatory effects on host mononuclear 
cells obtained from patients of SLE, TB and SLE-TB, as evidenced by a strong 
inhibition of the pro-inflammatory cytokine TNF-o. The results indicate an 
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GPx catalyzes the removal of hydrogen peroxide (Mesiter and Anderson, 1983). 
Decrease in GPx activity indicates impairment of hydrogen peroxide-neutralizing 
mechanisms (Rukmlr.i et ai., 2004). In the present study, reduced / suppressed 
GPx activity in patient monocytes that were untreated or treated with SN50/M 
was recorded, thereby concurring with earlier reports that substantial amounts of 
ROS are being generated in patient cells due to cellular activation (Islam et al., 
2004). Enhancement of GPx activity in monocyte cultures from patients with 
SLE, TB and SLE-TB after addition of NAC, a precursor of the in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. Surprisingly, 
GPx activity was observed to be further augmented when EGCG was co-cultured 
instead of NAC, indicating EGCG to be an effective natural antioxidant combating 
ROS, generated as a consequence of cellular activation in mononuclear 
phagocytes. Moreover, in continuation to the above, our data further shows the 
lipid peroxidation-induced augmented MDA levels in culture supernatants of 
monocytes from patients with SLE, TB and SLE-TB were appreciably suppressed 
or down-regulated with EGCG. 
Our results are strongly indicative for the appreciable correlation between 
autoimmune diseases like SLE and Mycobacterium tuberculosis infection. 
Inhibition ELISA results strongly suggests that all the TB positive sera selected in 
this study were having a high degree of specificity towards MTB Ag85B (30kDa). 
Similarly, our data show high degree of recognition of anti-DNA antibodies found 
in SLE sera by native dsDNA. The achievement of 50% inhibition in antibody 
activity in both the above diseases i. e. TB and SLE at a very low inhibitor 
concentrations are indicative for the presence of highly specific respective 
antibodies in all the sera selected for this study. 
One of the interesting findings of this study was that the SLE patients were found 
to be more susceptible to TB development than the vice-versa case. This is 
evident from the data indicating that autoantibodies found in SLE sera strongly 
recognized both native dsDNA as well as mycobacterial AgSSB SOkDa, whereas 
anti-TB antibodies found in TB sera strongly recognized only Ag85B 30kDa, 
whereas it exhibited low or negligible recognition with native dsDNA. However, 
antibodies found in sera of patients suffering with both TB along with SLE (SLE-
TB) revealed high specificity for both the antigens i. e. native dsDNA and MTB 30 
kDa. 
An attempt was also made to evaluate the immuno-binding by generating in-vivo 
conditions i. e. by using cultured monocytes that were infected with bacilli (TB 
patients) as well as monocytes from SLE patients. The high percent maximum 
inhibitions as well 50% inhibitions in anti-TB and anti-DNA activities at extremely 
low inhibitor concentrations are suggestive for the appreciably high affinity 
immuno-interaction occurring between anti-TB antibodies and anti-DNA 
autoantibodies with antigens in monocyte protein lysates as well as respective 
dsDNA of TB patients and SLE patients respectively. 
A striking finding in the present study is the EGCG as well as reduced 
glutathione-induced down-regulation in binding of anti-TB antibodies and anti-
DNA antibodies with antigens present in protein lysates prepared from monocyte 
of TB patients and SLE patients respectively. Similar actions of reduced 
glutathione in monocytes obtained from blood of patients having both TB along 
with SLE further substantiates the antioxidant-induced suppression in immuno-
binding. Furthermore, these results are correlating appreciably with the amount 
of TNF-a secreted in different monocyte cultures undertaken in this study. The 
importance of glutathione and its involvement in the above actions in monocytes 
of TB and SLE patients undertaken in our study could be best viewed by the 
following mentioned relevance of glutathione. Glutathione (g-
glutamylcysteinylglycine, GSH) is a sulfhydryl (-SH) antioxidant, antitoxin, and 
enzyme cofactor, which often attains millimolar levels inside cells, which makes it 
one of the most highly concentrated intracellular antioxidants. The reducing 
power of GSH is a measure of its free-radical scavenging, electron-donating, and 
sulfhydryl-donating capacity. Reducing power is also the key to the multiple 
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actions of GSH at the molecular, cellular, and tissue levels, and to its 
effectiveness as a systemic antitoxin (Meister et al., 1994). Experimental GSH 
depletion can trigger suicide of the eel! by a process knov\/n as apoptosis (Slater 
et a!., 1995). Antioxidants are the body's premier resource for protection against 
the diverse free radical and other oxidative stressors to which it invariably 
becomes exposed (Cross et al., 1987). The antioxidant defense system is 
sophisticated and adaptive, and GSH is a central constituent of this system. 
Nowhere is its presence more important than in the mitochondria. The liver 
seems to have two pools of GSH; one has a fast turnover (half-life of 2-4 hours), 
while the other is avidly retained with a halfrlife of about 30 hours (Meister et al., 
1995). The first corresponds to cytosolic GSH, the second mainly to 
mitochondrial GSH which is known to be more tightly held. 
Being directly in the path of airborne materials, the lung tissue is particularly at 
risk from oxidative stressors such as cigarette smoke, atmospheric pollutants, 
and other inhaled environmental toxins (Kidd, 1985). GSH and GSH-associated 
enzymes present in the epithelial lining fluid (ELF) of the lower respiratory tract 
may be the first line of defense against such challenges (Deleve and Kaplowitz, 
1990; Pacht et al., 1991). Sustained oxidative challenge to the lung results in 
depletion of GSH and other antioxidants from the lungs. 
As with other cell types, the proliferation, growth, and differentiation of immune 
cells is dependent on GSH. Both the T and the B-lymphocytes require adequate 
levels of intracellular GSH to differentiate, and healthy humans with relatively low 
lymphocyte GSH were found to have significantly lower CD4 counts (Kinscherf et 
al., 1994). Intracellular GSH is also required for the T-cell proliferative response 
to mitogenic stimulation, for the activation of cytotoxic T "killer" cells (Droge et al., 
1994), and for many specific T-cell functions, including DNA synthesis for cell 
replication, as well as for the metabolism of interleukin-2, which is important for 
the mitogenic response (Wu et al., 1994). 
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Experimental depletion of GSH inhibits immune cell functions, sometimes 
markedly (Fidelus and Tsan, 1987), and in a number of different experimental 
systems the intracellular GSH of lymphocytes was shown to determine the 
magnitude of immunological capacity (Droge et al., 1994). Thus intracellular GSH 
status plays a central role in the functioning of immune cells. In the auto-immune 
diseases of systemic lupus erythematosis (SLE) and rheumatoid arthritis (RA), 
and as seen in aging, T lymphocytes demonstrate depressed responsiveness to 
antigens and mitogens, perhaps because of insufficient IL-2 production (Fidelus 
and Tsan, 1987). Patients with RA have low blood sulfhydryl (-SH) status 
(Fidelus and Tsan, 1987), as did patients with Type II diabetes or with ulcerative 
colitis (Fidelus and Tsan, 1987). 
Chronic viral infections may also trigger GSH depletion in circulating immune 
cells. Patients chronically infected with hepatitis C virus have low GSH in their 
circulating monocytes. Monocyte GSH levels are abnormal in early HIV-1 
disease (Droge et al., 1997), then in patients with advanced disease the GSH 
levels normalized in monocytes but the GSH/GSSG ratio became abnormal. 
Significant decreases in the plasma levels of both cysteine and cystine has also 
been documented in subjects with HIV-1 infection (Droge et al., 1997). Since 
cysteine is a rate-limiting precursor for GSH synthesis, an associated decrease 
of GSH in the lung ELF was highly suggestive of a systemic GSH insufficiency in 
these subjects (Buhl et al., 1989). The most marked GSH decreases occurred in 
subjects who were asymptomatic but had CD-4 counts below 400. Both the 
abnormal cytokine expression and the progression to weight loss seen in HIV-1 
disease may be linked (at least in part) to abnormalities in the uptake of GSH 
precursors by immune cells of HIV-1 subjects, and/or to abnormalities in their 
synthesis of GSH. 
To have further in-sight, the present study involves utilization of dsDNA isolated 
from monocyte cultures of SLE, TB and SLE-TB patients that were either 
untreated or treated with EGCG, NAC, SN50 and SN50M, an in turn, employed 
131 
as antigens / inhibitors in immunoassays against anti-DNA SLE antibodies and 
anti-TB antibodies respectively. Thus, interesting important observations were 
made. We observed that purified anti-DNA antibodies from SLE patients 
exhibited high degree of recognition / specificity against dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively. However, this high 
magnitude specificity / binding of purified anti-DNA antibodies from SLE patients 
was reduced or suppressed appreciably towards respective dsDNA isolated from 
monocytes of patients with SLE, TB and SLE-TB respectively that were treated 
with EGCG, NAC or SN50. On the contrary, anti-TB antibodies exhibited high 
binding only with dsDNA isolated from monocytes of patients with TB, but failed 
to show any significant recognition / binding with dsDNA isolated from monocytes 
of patients with SLE. Furthermore, when monocyte cultures of SLE, TB and 
SLE-TB patients that were treated with EGCG, NAC and SN50, and in turn, 
respective dsDNA isolated and employed in ELISA, reduced or insignificant 
binding was observed against anti-dsDNA antibodies from SLE patients or anti-
TB antibodies from TB patients. Thus, in view of the fact that native DNA is a 
poor immunogen, and that, the exact trigger of anti-DNA production in SLE still 
remains poorly understood, where DNA has been thought to act only as a cross-
reacting antigen, the results indicate possible involvement of Mycobacterium 
tuberculosis protein(s) / nucleic acid antigens(s) in providing an alternate trigger / 
origin for autoantibody production in systemic lupus erythematosus (SLE). 
Moreover, the data generated in the present study is suggestive for the fact that 
- reactive oxygen species (ROS) generated as a consequence of stress of any 
kind in autoimmune SLE results in the activation of proinflammatory cytokine 
TNF-a, which in turn results in the production of anti-DNA auto antibodies. These 
SLE patients having high ROS levels become highly susceptible to MTB 
infection. Upon MTB infection, the ROS and TNF-a potentiates or activates the 
MTB 85B replication in SLE-TB patients. Such an activation of ROS or TNF-a 
and in turn the SLE and TB proliferation could be arrested or limited by the usage 
of EGCG- a green tea polyphenol and reduced glutathione as revealed by our 
1 - j i 
data. In conclusion, based on characterization studies, followed by 
immunological data, it can be inferred from the present study that: 
• There exist high basal levels of TNF-a in sera as well as in 
monocyte cultures of patients with SLE, TB and SLE-TB. 
• Activation of monocytes by M. tuberculosis infection in SLE patients 
induces the expression of both TNF-a at both the gene and protein 
levels. 
• Both RNI and ROI, induced early after infection of SLE monocytes, 
increases expression of TNF-a. 
• Activation of monocytes by M. tuberculosis initiates a cascade of 
events whereby a vicious circle may exist in which expression of 
host inflammation and mycobacterial products amplify one another. 
• EGCG (0-25 pg/ml) exhibited no toxic effect on the viability of 
human monocytes. 
• EGCG inhibits the expression of TNF-a protein production in a 
dose-dependent manner in 24 hr monocyte cultures from patients 
with SLE, TB and SLE-TB, and that, it is mediated mainly via NF-
KB. 
• EGCG ameliorates the glutathione peroxidase activity in monocytes 
from patients with SLE, TB and SLE-TB. 
• EGCG suppresses the augmented MDA levels in monocytes from 
patients with SLE. TB and SLE-TB. 
• All the M. tuberculosis and SLE sera involved in this study showed 
a high degree of specificity for Ag85B (30 kDa) and native dsDNA 
respectively. 
• Mycobacterial 30 kDa protein antigen (Ag85B) as well as protein 
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lysates prepared from monocytes of M. tuberculosis patients were 
recognized appreciably by anti-tuberculosis antibodies present in 
M. tuberculosis sera, whereas non-mycobacterial native dsDNA 
showed poor recognition with the same anti-tuberculosis 
antibodies. 
• On the contrary, both non-mycobacterial native dsDNA and protein 
lysates prepared from monocytes of SLE patients as well as 
mycobacterial 30 kDa protein antigen (Ag85B) were found to be 
recognized appreciably by anti-DNA autoantibodies present in SLE 
sera. 
• Furthermore, co-culturing of monocytes obtained frorp M. 
tuberculosis, SLE or M. tuberculosis-SLE with 10 nM of reduced 
glutathione showed amelioration of ROS and TNF-a induced 
actions, which in turn, subsequently suppressed the immuno-
bindings observed in monocytes of M. tuberculosis and SLE 
patients cultured without glutathione. 
• Our data shows that SLE patients are more susceptible to 
M.tuberculosis development, as ROS and TNF-a in SLE patients 
could activate the replication of Ag85B (30 kDa) after bacilli 
infection. 
• Finally, immunoaffinity purified anti-DNA antibodies from SLE 
patients recognized dsDNA isolated from monocytes of both SLE 
and TB patients, but on the contrary, anti-TB antibodies recognized 
dsDNA only from monocytes from TB patients but not SLE patients. 
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